header logo image


Page 698«..1020..697698699700..710720..»

Turkish doctor creates first see-through 3D maps of human kidney and eye – Daily Sabah

February 18th, 2020 5:54 pm

A Turkish doctor and his 15-member team have managed to render transparent 3D models of the human eye and kidney in what the scientific community heralds as an important development in organ production, the fight against cancer and even the mapping of the brain.

Genetics and neuroscience specialist Dr. Ali Ertrk, the director of the Institute for Tissue Engineering and Regenerative Medicine at Helmholtz Zentrum Mnchen and also principal investigator at the Institute for Stroke and Dementia Research at Ludwig Maximilian University's hospital, talked about their pioneering project in which they used microscopic imaging technology to reveal underlying complex structures of human organs by making them see-through. Their findings were published in the scientific journal Cell on Feb. 13.As part of the final stage of their project, Ertrk said they developed a new technology called SHANEL (Small-micelle-mediated HumAN organ Efficient clearing and Labeling) which is essentially a 3D laser microscope that can scan large tissues. Up until now, scientists had only managed to obtain cellular views of intact mouse organs in 3D. The chemicals used to turn mouse organs see-through did not work on human parts because of the accumulation of insoluble molecules including collagen over many years. After many trials, the team discovered CHAPS, a detergent that could seep into thick human organs and turn them transparent.

"We started these studies three years ago. In order to make 3D maps of these organs at a cellular level, we first had to make them visible under a laser microscope. Last year, we succeeded in making organs donated from cadavers transparent with various chemical solutions, as if turning milk into water," Demirren News Agency (DHA) quoted Ertrk as saying."We also developed an artificial intelligence algorithm that reduces the analysis of millions of images that we have obtained from the microscope, which would normally take humans centuries to analyze, down to just a few hours. Thus, for the first time in the world, we were able to make a 3D map of the human kidney and eye at the cellular level," he added.

The method could become a key technology for mapping intact human organs in the near future and hence "dramatically accelerate our understanding of organs such as the brain, their development and function in health and disease," explained Ertrk.

He said they believe that Shanel can help map the human brain at a molecular level and produce artificial human organs at a cellular level thanks to the 3D-bioprinting technology. Ertrk said they are currently working on mapping major organs such as the heart, kidney and pancreas.

"There is a huge shortage of organ donors for hundreds of thousands of people. The waiting time for patients and the transplantation costs are a real burden. Detailed knowledge about the cellular structure of human organs brings us an important step closer to creating functional organs artificially on demand," the biotech specialist said in a press release.

Read more from the original source:
Turkish doctor creates first see-through 3D maps of human kidney and eye - Daily Sabah

Read More...

Edited Transcript of VRT.AX earnings conference call or presentation 17-Feb-20 10:00pm GMT – Yahoo Finance

February 18th, 2020 5:53 pm

Half Year 2020 Virtus Health Ltd Earnings Call

Greenwich Feb 18, 2020 (Thomson StreetEvents) -- Edited Transcript of Virtus Health Ltd earnings conference call or presentation Monday, February 17, 2020 at 10:00:00pm GMT

TEXT version of Transcript

================================================================================

Corporate Participants

================================================================================

* Glenn Powers

Virtus Health Limited - CFO & Company Secretary

* Susan Channon

Virtus Health Limited - CEO, MD & Director

================================================================================

Conference Call Participants

================================================================================

* David Andrew Stanton

Jefferies LLC, Research Division - Equity Analyst

* Thomas Godfrey

UBS Investment Bank, Research Division - Analyst

================================================================================

Presentation

--------------------------------------------------------------------------------

Operator [1]

--------------------------------------------------------------------------------

Thank you for standing by, and welcome to the Virtus Health Limited Half Year FY '20 Results Conference Call. (Operator Instructions)

I would now like to turn the call over to Ms. Sue Channon, CEO. Please go ahead.

--------------------------------------------------------------------------------

Susan Channon, Virtus Health Limited - CEO, MD & Director [2]

--------------------------------------------------------------------------------

Thank you, and welcome to the Virtus Health FY '20 Half Year Results, and thank you for joining us. Virtus has demonstrated resilience and outperformed overall market volume growth in Australia. We have focused on improving profitability through cost reduction initiatives, which will be realized in future periods, and our investments in infrastructure in FY '19 have facilitated business development opportunities and growth. It's Virtus' diversified model, scale and geographical reach that provides an unrivaled platform for participation in all key fertility segments, both domestically and internationally, and it has delivered.

Story continues

Moving to Slide 4 and the financial results highlights. Virtus overall fresh cycle growth for the half year was up 1.3% with a total of 10,649 fresh cycles compared to 10,513 cycles in the prior corresponding period. Revenue was up 1% to $142 million on the prior corresponding period, and EBITDA was up 21.9% to $39.5 million, noting that $7.4 million of the increase was the result of adopting the new lease accounting standard.

Australian segment EBITDA increased 18.8% to $39.7 million. Again, $5.9 million of this increase was a result of the new standard. And International segment EBITDA increased 22.7%. Again, $1.5 million of this increase was from the adoption of the new lease standard.

NPAT attributable to ordinary equity holders was up 2.3% to $15 million with earnings per share up 2.4% to $0.1865. Headline earnings have been impacted by fair value gains on put options, lower interest costs and CEO transition and recruitment costs. The company has declared an interim dividend of $0.12 per share fully franked, unchanged from the prior year and payable on the 16th of April.

Turning now to Slide 5. Against the backdrop of a competitive business reproductive services market, we have responded accordingly and maintained our Australian market leadership position. We have adjusted our service model to the patient mix and changes in the market and continued the activities we started in FY '19 to remove cost in the business, which will deliver further benefits in future periods. As a result of our focus on patient care models, Virtus outperformed overall market growth in Australia, and cycle activity in the half increased 2.7% compared to an increase in Virtus available market of 1.2%. Notably, Australian IVF clinic EBITDA increased 4.5%, excluding the impact of the AASB 16 lease standard.

We have delivered strong growth in our Australian TFC low price clinics. And while our Victorian premium cycles were stable and Queensland grew, lower premium cycle volumes in New South Wales have impacted EBITDA, pathology revenue and IVF-related Day Hospital revenue in New South Wales. The investments made through FY '19 new Day Hospital facilities and our focus on business development are starting to deliver, with non-IVF Day Hospital procedure volume increasing 5.7%. International operations maintained EBITDA despite softer volumes, and we have seen EBITDA improvements in Ireland, Singapore and the U.K.

Management's focus on cost-out initiatives for margin improvement continued. However, overall corporate costs were impacted by CEO transition, recruitment and restructuring initiatives, which will deliver improved EBITDA margins in future periods.

Moving to Slide 6. And the Australian segment performance saw revenue up 0.3% to $112.8 million. And Australian segment EBITDA, including the impact of the new lease standard implementation of $6 million, increased to $39.7 million. The initiatives that we'll continue to deliver on this improved position are summarized on Slide 7.

So moving to Slide 7. In our summary at the end of FY '19, we noted that our focus in Australia will be on defending and building premium services, growing low price volumes, growing diagnostic revenue and growing non-IVF Day Hospital revenue.

Available market share increased to 40% in the first half compared to June 2019 closing position of 39.6%. Virtus cycle growth is 2.7% year-to-date compared to an available market growth of 1.2%. Virtus premium service remains our focus. And year-to-date, our premium cycle volume is up in 3 states of Queensland, Victoria and the ACT. Softer market conditions led to a reduction in our New South Wales and Tasmanian volumes. However, additional doctor recruitment is in progress in both states, in parallel with leadership changes guiding operational and cost-out initiatives.

Our TFC low price clinic saw volume growth of 30.2%, with low price cycles now representing 22% of overall volumes compared to 17.3% in the prior corresponding period. Overall, Australian Reproductive Services EBITDA margins have been impacted slightly and are down 0.5%, excluding the AASB 16 lease impact.

Diagnostic initiatives have not yet delivered with revenue flat as a result of lower pathology and PGT volumes, resulting in a less favorable revenue mix. Cost management initiatives have been implemented to align with volume softness, and there's a focus on increasing testing utilization within the new Revesby laboratory to drive internal and external referrals and utilization.

In our Day Hospital, non-IVF revenue growth of 6.8% has been achieved following business development initiatives in the 2 new Day Hospitals commissioned last year. Endoscopy procedures have been established in both facilities and are expected to deliver improved performance in the second half.

Moving to Slide #8 and the Australian ARS operations. Virtus Australia's overall cycle activity increased 2.7% in the first half to 8,302 cycles compared to an available Eastern Seaboard market volume increase of 1.2%, with a resulting EBITDA increase of $1.3 million. Virtus Victoria grew 10.2% on the prior corresponding period against a market growth of 1.7%. Premium cycle volume was stable with growth predominantly in low-cost services. Virtus Queensland grew 6.2% on the prior corresponding period against the market growth of 4.4%. Virtus New South Wales, including the ACT, declined by 3.4% on the prior period against the market decline of 0.5%. We had some movement of a few doctors due to retirement and international relocations that impacted this. And Virtus Tasmania declined by 20.3% on the prior period against a market decline of 5%, doctor resources again being the issue in Tasmania.

Virtus has continued to proactively target the low-cost segment with ongoing service model and pricing reviews and delivered a volume increase of 30.2% across the fertility center network with improved performance across all states. The TFC now represent 22% of Virtus Australia cycle volume against 17.3% in the prior period. And whilst we've experienced a small decrease in our EBITDA margins overall as a result of our targeted low price initiatives, EBITDA margins within our TFC to remain in excess of 35%.

Moving to Slide 9. Virtus Diagnostics revenue increased 0.2%, and EBITDA decreased 30.2% over the prior period as a result of less favorable revenue mix and cost. This was caused by continued softness in PGT utilization declining to 12.9% of fresh cycles from 14.6% in the prior corresponding period, impacting margin, and increased compliance costs as a result of the change in NPAAC supervision requirements. The first half FY '20 costs are recorded with a full half year impact compared to only 3 months in the prior period.

We will focus on further growth in Diagnostics by driving internal and external referrals to utilize increased capacity and expanded testing capability in the relocated laboratory supported by the additional scientific and pathologist resources; the introduction of new technologies for noninvasive PGT, which continues through the validation process and molecular genetics; and cost-out initiatives to align with volume.

Diagnostics continues to be an important part of our Virtus integration platform, and we are focused on growing the utilization of these investments made through FY '19 for an improved performance.

Moving to Slide 10 and the day -- Australian Day Hospital operations. The Day Hospitals experienced a difficult year in FY '19 as a result of the delays in commissioning the planned facility development. However, the first half FY '20 has seen an improvement in utilization and business development continues, delivering an increase of 6.8% on the prior corresponding period in non-IVF Day Hospital revenue across all Specialist Day Hospitals.

Overall Day Hospital EBITDA was flat as non-IVF growth was offset by lower IVF procedures impacted mainly by softer premium cycle volume in New South Wales. Business development has delivered a $300,000 EBITDA improvement over the prior period in Alexandria as more non-IVF surgery is secured. And whilst Hobart Specialist Day Hospital is still in early stage of business development, an operational restructure was completed in December 2019. And with the first endoscopy list commencing on the 13th of February, the outlook is more positive.

Moving to Slide 11. We have continued to diversify our revenue since listing through our international operations, which are now 21% of group revenues. We have made good progress through the half and have delivered earnings improvement in 3 territories: Ireland, Singapore and the U.K. International segment revenue is up 3.5% to $29.2 million, and segment EBITDA is $6.8 million.

And looking at the Irish operations on Slide 12. In Ireland, despite fresh cycle volume softness, we have seen EBITDA improvement of 17.1% on the prior period as a result of cost management initiatives. 1,075 cycles performed in the half compared to 1,094 in the prior period. Revenue was flat at EUR 10.5 million despite the lower fresh cycle volumes, which were offset by an increase in frozen cycles.

Moving to Slide 13. In our Danish operations, EBITDA overall was down on the prior period. 849 cycles performed in the half against 930 in the prior period. Revenue across the Danish clinics was down 7.5% at DKK 25.6 million. EBITDA, local currency, was down 45.9% on the prior period. Cycle volume was impacted by changes to Swedish donor regulations, reducing IVF tourism into Denmark. Short-term doctor resourcing issues impacting performance in Aagaard have now been addressed, and the clinic is fully resourced at December 2019. Management resources have been strengthened in Denmark to focus on business development and growth.

Moving to Slide 14. Complete Fertility has improved revenue and EBITDA performance this half from stronger donor activity and improved activity from the National Health Service. Complete Fertility performed 215 fresh cycles against 228 in the prior period, and revenue was up 13.4%. EBITDA was up 125% over the prior period driven by revenue initiatives and effective cost management.

And Singapore continued its positive performance with 208 cycles against 176 in the prior period. Revenue is up 13.5%, and EBITDA is up 77.4% on the prior period. The Singapore team has just celebrated their fifth year anniversary and continues to delight with consistently high patient survey results and the NPS score leading our group and benchmark for pregnancy and live birth success rates the highest across our network.

I'll now pass you over to Glenn Powers, CFO, to provide the detailed financial summary.

--------------------------------------------------------------------------------

Glenn Powers, Virtus Health Limited - CFO & Company Secretary [3]

--------------------------------------------------------------------------------

Thank you, Sue. Good morning, everybody, and turning to Page 17. So the statutory results, obviously, for Virtus, as with most companies, there is quite an influence of AASB 16, the new leasing standard. I think we just put it straight down to the bottom, the profit after income tax attributable to ordinary equity holders, that is up by 2.3% overall. The net AASB 16 impact on that was to reduce that NPAT number by approximately $200,000. Obviously, within the body of the P&L, you've got movements in terms of the segment EBITDA, the depreciation number and also the interest number. And those are noted at the bottom of the page, the actual numbers.

Looking at Slide 18, we just call out the net movement from noncash transactions, transaction expenses and also, this time, the CEO transition costs. And you can see there, there was a fair value adjustment related to the settlement of the final options in respect of Ireland and Tasmania. And I think the other cost movements are pretty much self-explanatory.

Slide 19, we do provide a detail of our AASB 16 adjustments. I don't propose to go through that in detail, but you can see there is that net decrease or that net impact to the actual profit after income tax of $0.02 million.

Turning to Slide 20. I think Sue has covered, obviously, a lot of the key drivers for the revenue and group EBITDA. I think a couple of key points to note. Firstly, Australian IVF clinic EBITDA increased by 4.5%. So we think that's a pretty positive result given the change in mix. So we have seen continued shift and increase towards more low price IVF. But the businesses have responded very well in terms of their operational management, and we have seen that 4.5% increase in our core clinic EBITDA.

We also saw EBITDA growth in Ireland. That was at 17%, so that was a very, very positive result there. And Singapore has continued to improve its EBITDA. U.K., which gave us a little bit of an issue last year, U.K., we've actually seen a recovery in performance and, again, a combination of good development of the business around our core IVF activity but also good cost management as well.

Two main headwinds, really, that we saw in the second -- in the first half with Diagnostics EBITDA and the impact of a shift in revenue mix away from the PGT activity. And also, as Sue said, we absorbed the full year -- a full half year of the compliance cost increase in this half. The other area was very much Denmark. Denmark, the doctor resource change in the Swedish donor market were both significant factors in the first half. But the businesses are very much set up now for the second half. We have doctors in place. We've added doctors in both clinic locations. So we do anticipate an improvement in performance in our Danish businesses in the second half.

I think we've covered the leasing position extensively. So again, although the movements don't look significant, in some ways, I think there are some positives around individual clinic performance and particularly our core Australian business.

Cash performance on Slide 21. We actually saw a very focal performance compared to the prior year comparison. And again, unfortunately, leasing does impact 2 or 3 numbers there: so the group EBITDA number, the lease interest number and also the lease principal payments number. They all flowed from the AASB 16 adjustments. But some of the core factors that actually show -- led to that improved cash performance, lower CapEx. Last year, fiscal year '19 was a big year in terms of capital expenditure. This year is more modest. And most of the CapEx this year continues to be around technology and laboratory enhancements, primarily EmbryoScope in 2 or 3 locations we've added the facility. We also saw improved working capital in this half, and that contributed to a turnaround of $9 million in free cash flow after dividends compared to the prior year.

Slide 22, the statement of financial position. Again, AASB 16, obviously, it impacts the net asset -- net financial position. So the net asset reduction includes a net impact of $8.7 million resulting from that new accounting standards, and that's covered in the first part of the slide. Dividend proposed, no change in this half year, so the dividend of $0.12 per share, fully franked, will be payable on the 16th of April. Sue?

--------------------------------------------------------------------------------

Susan Channon, Virtus Health Limited - CEO, MD & Director [4]

--------------------------------------------------------------------------------

Thanks, Glenn. So moving to Slide 23 and our summary. Fertility, as we have talked about previously, affects 1 in 6 couples' reproductive age worldwide, and the social and demographic factors that contribute to this global dynamic continues to drive demand for ARS. Our strategy has been to ensure that Virtus has the platform to self-sustain ongoing growth. And investments in people, technology and additional day hospital and diagnostic capacity support this strategy, the outcome of which is evident in our first half FY '20 results. As we continue to develop our approach and model to ensure we remain relevant to the patients we treat and the markets in which we operate, our network is well established in the all-patient demographics. Revenue growth will be achieved through a combination of service expansion and market penetration.

Our strategy is to focus on defending and building the premium ARS business, and we remain committed to growing our service and presence within the low price segment. Our day hospital strategy has seen a focus on attracting non-IVF surgical activity to our improved facility, and this is delivering. Our diagnostic throughput will be enhanced through our research into NIPT and business development activities to maximize internal and external diagnostic and genetic referrals. We have made good progress through the half across the international business and have addressed performance, resourcing and cost-out initiatives. And our international operations continue to contribute positively to the diversification of our revenue.

Our focus on margin improvement is ongoing with efficiencies and cost savings expected through recent management restructures and a greater emphasis on process improvements to ensure optimal patient care and experience. We have a very clear program of work to drive earnings growth through our cost-out initiatives, many of which have been completed in the first half. We are well positioned to deliver further earnings improvement across Virtus in the second half.

As you know, Kate Munnings will join Virtus on the 4th of May. Kate, most recently Chief Operating Officer with Ramsay Health Care Limited's Australian business, has a successful track record leading commercial improvement, organizational and business transformation across multiple sectors and industries. Kate's relevant experience, especially alongside specialist doctors, means she's well equipped to lead Virtus Health and the continued delivery of exceptional services to patients. I had the pleasure of having dinner with Kate last week, and I believe the organization is in good hands. I am confident she will continue to lead Virtus successfully into the next phase.

Glenn and I will be happy to take questions regarding Virtus Health results now.

================================================================================

Questions and Answers

--------------------------------------------------------------------------------

Operator [1]

--------------------------------------------------------------------------------

(Operator Instructions) Our first question is from David Stanton, Jefferies.

--------------------------------------------------------------------------------

David Andrew Stanton, Jefferies LLC, Research Division - Equity Analyst [2]

--------------------------------------------------------------------------------

First, I'd like to say a big thank you to Sue for all her help over the years. You'll be greatly missed. But my first question is, as an overall statement in Australia, can you give us an idea of why you think the premium market as you see it is declining?

--------------------------------------------------------------------------------

Glenn Powers, Virtus Health Limited - CFO & Company Secretary [3]

--------------------------------------------------------------------------------

Yes. I think the -- if we look at it -- well, the interesting thing is that it's not across -- it's not consistent across states. For example, we actually saw good growth in our Queensland premium service in the first 6 months. Victoria, we were stable in terms of the market. I think if you look at New South Wales, which is obviously the biggest market, the market was down generally in New South Wales. So of all the 3 big states, New South Wales was, by far, the weakest state in terms of market performance. So okay now, I don't think we feel necessarily that the premium is in decline. There's been a bit of talk overnight around fertility rates. And I think it is important just to note that the utilization rate of IVF continues to increase. And we've seen that again in the latest reports and comparing [ANZA] birth information compared to national birth numbers. So I think what we are just continuing to see is premium is possibly stable, but the growth in the sector does continue to be TFC/low price IVF. So -- and I think our record in the first 6 months shows that. Whether in New South Wales -- I think there may have been some local market conditions that have impacted the general state of the market in New South Wales, I think we'll see that over time in the next 6 to 9 months.

--------------------------------------------------------------------------------

Susan Channon, Virtus Health Limited - CEO, MD & Director [4]

--------------------------------------------------------------------------------

And David, sorry, as we've talked about previously, there will always be patients where the low-cost service is just not suitable. So the PGs, the genetics, et cetera, where patients will always need access to those higher-end services.

--------------------------------------------------------------------------------

David Andrew Stanton, Jefferies LLC, Research Division - Equity Analyst [5]

--------------------------------------------------------------------------------

Very good. Understood. And stop me if I'm wrong, regarding international, there were like 1 or 2 that weren't like this, but international cycles have decreased pretty much across the board. Is it -- would it be fair enough to say that that's due to the rest of the world playing catch-up on increasing the amount of frozen cycles or the fresh cycles, please, that we saw maybe 2 years ago in Australia?

--------------------------------------------------------------------------------

Glenn Powers, Virtus Health Limited - CFO & Company Secretary [6]

--------------------------------------------------------------------------------

Yes, we have seen a little bit of that. Certainly, in Ireland, we've seen that shift on more frozen cycles. So the business mix has changed a little bit. Again, if you look at the impact on our results then, our Irish business has improved EBITDA by 17% in the half. So it's sort of a bit of a natural evolution, it comes to a finite point. And we've seen that in the Australian sector. A couple of years ago, people were saying that it will be a one-for-one relationship between fresh and frozen, and that hasn't transpired. So yes, we've seen a little bit of transition as well in the Danish market. I think if you look at the Danish market, our volume decline, which is a good part of the decline in the international cycle, it has been more around doctor resource. So I think we feel we've got the doctor resource in place in both of our clinics now, and we'd like to think that we can see some business development activities, particularly in Denmark, in the next few months. And we'd like to think that we'll see our Danish business grow cycles in over the next 12 months.

Link:
Edited Transcript of VRT.AX earnings conference call or presentation 17-Feb-20 10:00pm GMT - Yahoo Finance

Read More...

Belarus, Egypt to sign intergovernmental program in education – Belarus News (BelTA)

February 18th, 2020 5:53 pm

MINSK, 17 February (BelTA) Belarus and Egypt are planning to sign an intergovernmental executive program in higher and postgraduate education, Ambassador Extraordinary and Plenipotentiary of Belarus to Egypt Sergei Terentiev said in an interview with BelTA.

The ambassador spoke about the Belarus-Egypt relations in education. Thus, the National Academy of Sciences of Belarus and the Academy of Scientific Research and Technology of Egypt signed a cooperation agreement to implement five joint research projects in crop farming, nanomaterials, molecular genetics and metallurgical science.

Belarus also invited Egypt to implement projects in e-government, digital transformation, computer games and training of IT personnel. Last year Belarus issued, for the first time, educational grants to citizens of Egypt for the bachelor and master's degree programs in Belarus.

The diplomat noted that some Belarusian universities signed agreements on cooperation with Egyptian colleagues. Belarusian National Technical University (BNTU) and Tabbin Institute for Metallurgical Studies are working to set up a joint engineering department.

Currently the parties are working to arrange a visit of the minister of higher education and scientific research of Egypt to Belarus in 2020.

Read more:
Belarus, Egypt to sign intergovernmental program in education - Belarus News (BelTA)

Read More...

The Chemical Imbalance Theory of Depression: Where Is It Going? – James Moore

February 18th, 2020 5:53 pm

The spurious chemical imbalance theory of depression is arguably the most destructive thing that psychiatry has ever done. Worldwide, millions of individuals are taking antidepressants, often with a cocktail of other drugs, because they have been told the blatant falsehood that they need the pills to combat a brain illnessa real illness just like diabetes.

Many of these individuals were told the additional lie that they needed to take the pills for life and are now addicted to the products.

At the present time, some psychiatrists and psychiatric facilities are backing away from the hoax. Most of these recantations take the form: We didnt mean it literally. The chemical imbalance thing was just a metaphor.

But what needs to be stressed is that the impetus for these diluted recantations came, not from psychiatry, but rather from the anti-psychiatry movement. It was the thousands of protesting voices that finally persuaded psychiatry that some backing off was needed, particularly as no proof of the theory had ever been uncovered.

The response from psychiatry, however, has not been commensurate with the damage done. What we need to see are full page ads in all major newspapers and cyber news outlets acknowledging that the chemical imbalance theory was a hoax; that it induced millions of people worldwide to take these drugs; and that it was developed and propagated to increase psychiatrys prestige and earnings. But thats not what we are seeing.

Instead, the general response from psychiatry continues to be one of denial, minimization, and excuse-making. The very eminent and learned Ronald Pies, MD, is the master of denial in this area, but minimizers and self-excusers abound. We are told that patients needed a simple formula for understanding their problems. They didnt. They needed the truth. We are told that patients needed a biological explanation to reduce stigma and alleviate their feelings of guilt. They didnt. They needed valid explanations. Besides, biological explanations actually increase stigma (here, here, here, and here).

The essential point is that as the drugs began to come on stream in the 50s, 60s and 70s, psychiatry needed illnessesreal illnesses with clear-cut biological etiologiesto cash in on the pharma-generated bonanza. Real illnesses were not to hand, so they invented their various chemical imbalance theories and promoted them as fact with all the vigor and energy that they could muster. Since then, psychiatrists have produced a truly overwhelming volume of research all aimed at proving the theory correct, but with no success. The simplistic shortage-of-serotonin-in-the-brain nonsense remains stubbornly unproven. As mentioned above, psychiatrists have backed off the more blatant expressions of this theory, but, remarkably, the treatments remain the same: Take these pills every day and come back in three months for more.

All of which is very interesting. But of even more interest is the recent development of a new approach to validatingor rather attempting to validatepsychiatric illness.

In JAMA Psychiatry, October 2019, Kenneth Kendler, MD, published an essay titled From Many to One to Many-the Search for Causes of Psychiatric Illness. Dr. Kendlers essential thesis is as follows. Prior to about 1850, causes of illness were anecdotally recorded from individual cases, resulting in long and diverse lists for all disorders. In the second half of the nineteenth century, single causes were found for many infectious diseases. Causal thinking shifted from multicausal approaches to monocausal theories of etiology. Dr. Kendler writes, Indeed proving monocausal etiology became a way to establish the legitimacy of a disorder. In the mid 20th century, general medicine shifted to a chronic disease model in which paradigmatic disorders, such as cancer and cardiovascular disease, were shown to be highly multicausal. Psychiatry, however, continued to pursue monocausal theories in their attempt to legitimize their activity. Despite ample evidence to the contrary, monocausal thinking continues to influence our field, for example, in the popular but improbable view that we can, with a few key advances, move easily from descriptive to etiologically based diagnoses.

Dr. Kendler works for Virginia Commonwealth University. He is a Distinguished Professor of Psychiatry, Professor of Human Genetics, and Director of the Virginia Institute of Psychiatric and Behavioral Genetics. He served on the DSM-III-R Work Group, on the DSM-IV Task Force, and on the DSM-5 Work Group for mood disorders.

Dr. Kendlers essay highlights two main themes: firstly, that psychiatry is not blameworthy in the promotion of spurious and monocausal etiologies; and secondly, that even though the quest has failed dismally, this is not a problem because a multicausal approach is better anyway.

Here are some pertinent quotes from Dr. Kendlers paper, interspersed with my thoughts and observations.

The second epidemiologic phase, termed infectious disease, had as its paradigm the germ theory, lasted roughly from 1850 to 1950, and was dominated by monocausal etiologic theories in which the relationship between putative etiologic agents and specific diseases was one to one (although most investigators recognized such modifying factors as host resistance). The third epidemiological phase, termed chronic disease, had a dominant black box paradigm. It incorporated a multifactorial disease model for what was termed chronic noncommunicable diseases (eg, diabetes, heart disease, certain forms of cancer, and hypertension), diseases often associated with particular lifestyles that could not be explained by a single salient causal factor. In this paradigm, the goal of epidemiology was to determine the magnitude and causal nature of the associations between a wide range of putative risk factors and these chronic noncommunicable diseases. This phase began around 1950 and has lasted until current times. (p 1087)

The essential point that Dr. Kendler is making here is that there is a fundamental distinction between these two phases. But is this really so? Let us compare scarlet fever, a classic monocausal infectious disease, with diabetes, which is the first example Dr. Kendler gives of a multicausal chronic disease.

Scarlet fever is caused by a streptococcal infection of the throat, while diabetes is widely considered to arise from many causes, or risk factors, as they are sometimes called. These include inheritance, lifestyle factors, and diet. However, the essential cause of diabetes is an inability of the pancreas to produce enough insulin to adequately process and utilize the sugar in the blood stream. This in turn stems from a damaged or compromised pancreas, ingestion of more sugar than the pancreas can cope with, or other causes. When considered in this light, diabetes is a monocausal illness, even though there are multiple pathways to the final cause.

Applying the same logic in reverse, one can make a case that scarlet fever is multicausal. Firstly, the individuals throat has to be exposed to the streptococcal infection. Secondly, the germ has to survive the initial immune system response. Thirdly, as hand-washing is one of the major protections against contracting this illness, anything that militates against frequent hand-washing could be considered a cause, e.g., living in crowded unsanitary conditions.

In addition, the time period leading up to the contraction of an illness can be analyzed and re-analyzed almost indefinitely. Any incident or event in that time frame has the potential to be considered a contributing cause. Let us say, for instance, that a child contracted scarlet fever at a birthday party given by one of his friends. We could legitimately say that the invitation caused the illness; or that the childs acceptance of the invitation was the cause. Or let us become even more imaginative and say that the child in question was rather shy and didnt want to go to the party, but was prevailed upon by his parents to do so, in the belief that it would do him good. So the illness was caused inadvertently by the parents! And so on.

Back to Dr. Kendlers essay.

During the second half of the 20th century, the approach to disease causation of major parts of psychiatry was out of step with the rest of medicine and medical epidemiology. Instead of multicausal models, the rising and soon to be dominant field of biological psychiatry pursued monocausal models for their major disorders. (p 1088)

The reader will have no difficulty seeing where this is going. Psychiatrists were chasing single causes, for their so-called illnesses, when they should have been looking for many causes. So the great failure of psychiatry to deliver the promised causes wasnt a failure at all. They were simply looking for the wrong kind of explanation. Butand this is the point that Dr. Kendler glosses overit wasnt a benign error. Psychiatry needed clear-cut biological explanations in order to take advantage of the drugs and to establish themselves as bona fide doctors. In this regard they routinely prioritized their own guild interests over the welfare of their clients.

In the early to mid-1960s, through histofluorescence stains, the cell bodies and neuronal pathways of the 3 monoamine neurotransmitters were identified: dopamine, norepinephrine, and serotonin. This further spurred the development of 3 long-lived monocausal neurochemical theories for psychiatric illness. All were proposed in the mid-to-late 1960s: the catecholamine hypothesis of affective disorders, the dopamine hypothesis of schizophrenia, and the serotonin hypothesis of depression. Although based on a range of evidence, the primary support for these theories was reasoning backward from therapeutic mechanisms to etiology. That is, for Parkinson disease the logic was sound: clarification of cause leading to a proposed treatment. By contrast, psychiatry followed the more problematic approach of extrapolating backward from a proposed mechanism of treatment to the cause of the disease. Although the original articles proposing these theories were couched in qualifications, as a psychiatry resident in the late 1970s, I was taught these theories as monocausal explanations. Schizophrenia was caused by excess dopamine transmission. Decades later, I would commonly see patients who would say some version of my psychiatrist said I have a chemical imbalance in my brain and then proceed to summarize one or more of these theories. It is now widely accepted that these theories, claiming a dominant causal pathway to illness, are false although debate continues regarding the dopamine hypothesis. (p 1088) [Emphases added]

Theres a lot in this quote. Firstly, note the phrase Although based on a range of evidence. In fact the evidence supporting these chemical imbalance theories was flawed, i.e. it was not evidence at all. Secondly, note the sentence By contrast, psychiatry followed the more problematic approach of extrapolating backward from a proposed mechanism of treatment to the cause of the disease. [Emphasis added] This was not a more problematic approach; it was a bogus approach; a hoax. And if the psychiatrists who promoted these theories couldnt see the deception, then they had no business presenting themselves as a helping profession. It becameand perhaps still isroutine for mental health workers who drew attention in case conferences to critical psychosocial realities to be told by the psychiatrists that first we have to treat the depression, which invariably meant drugs or electric shocks.

Although the original articles proposing these theories were couched in qualifications, as a psychiatry resident in the late 1970s, I was taught these theories as monocausal explanations. (p 1088)

Dr. Kendler did his psychiatry residence at Yale University, during which, he tells us, he was taught the various chemical imbalance theories, presumably as valid, factual explanations. This seems straightforward enough, and presents no surprises. But there is some ambiguity. If I were to say that my father taught me how to ride a bike, I am actually making two statements. Firstly, I am asserting that my father expended some time and effort in this process, and secondly, that his efforts were successful. In his essay, however, Dr. Kendler leaves this issue vague. Did he believe the hoax, and did he in turn foist it on his customers? It is obvious that Dr. Kendler is a very bright person and, given the fact that the original articles proposing these theories were couched in qualifications, it is reasonable to believe that he did see through the whole sordid deception. So what did he say to the trusting victims who parroted back the bogus theories to him? Did he tell them the truth? Or did he play along?

It is not my intention to pressure Dr. Kendler on this matter. Economics can make cowards of us all. But if he genuinely wants to promote honesty and integrity in this area, it would be helpful if he were to write an expos of sorts concerning the pressures he experienced in these matters during his psychiatric residency at Yale. Such an endeavor would be unlikely to endear him to his colleagues, but would shed light on a facet of psychiatry that has for too long been kept hidden, and might even encourage other psychiatrists to follow suit.

Psychiatry has had a long-term love affair with monocausal theories of illness dating at least from the late 19th century, heavily influenced by our success at the identification and effective eradication of GPI [general paresis of the insane]. In the latter half of the 20th century, with both neurochemical and molecular genetic theories of illness, our enthusiasm for monocausal theories outran our common sense. Emerging from decades of psychoanalytic dominance, we were deeply committed to reestablishing our medical legitimacy. What better way to show that we treated real diseases than to show that they were monocausal? (p 1089)

There is a distinct exculpatory tone to this passage. Instead of acknowledging that psychiatrists were systematically deceiving their customers for their own benefit, Dr. Kendler tells us that it was just a long-term love affair, in which their enthusiasm for monocausal theories outran [their] common sense.

Indeed, as mentioned earlier, this exculpatory stance is one of the dominant themes of the essay. Here are some additional quotes:

Our long yearning for monocausal theories of etiology drives, at least in part, our heartfelt calls for the abandonment of our descriptive nosologic systems in favor of an etiologic model. (p 1089)

There have not been heartfelt calls or long yearning from psychiatry on this matter. Rather, they simply declared the matter resolved, and promoted the chemical imbalance theories as fact. I have written extensively on this subject here.

This search has 2 prominent phases, both fueled by new scientific developments. The first was neurochemical. The stage was set in 1957 by Montagus discovery of dopamine in brain tissue quickly followed, in 1960, by the dramatic finds from Ehringer and Hornykiewicz of the decreased content of dopamine in the postmortem brains of patients with Parkinson disease. Here was a major neurologic disorder fitting apparently into a monocausal neurochemical theory. What could be more exciting for the then young and ambitious field of biological psychiatry? (p 1088) [Emphasis added]

So the systematic, self-serving, and widespread deception perpetrated by psychiatry stemmed from their excitement! How eminently understandable.

The second wave of monocausal theories in psychiatry was genetic. Despite much evidence from family studies that major psychiatric disorders did not segregate in pedigrees as expected for a mendelian condition, the first successful linkage study of Huntington disease in 1983elicited intense excitement in psychiatric genetics and launched a large number of linkage studies, especially of schizophrenia and bipolar illness. (p 1088) [Emphasis added]

Even more excitement!

Yet the ghost of GPIof monocausal psychiatric disorderslurks in our memory. To this day, it influences our nosologic thinking. It makes us too willing to adopt a monocausal perspective in our clinical work and in our explanations of psychiatric disorders to patients. Monocausal thinking continues to support hard reductionist approaches that seek the cause of our major disorders and is one of several factors inhibiting collaborative psychiatric research work across scientific levels. (pp 1089-1090)

So it is the ghost of GPI lurking in psychiatrists collective memories that inhibits them from acknowledging the non-medical nature of depression, painful memories, paranoid thinking, distractibility, etc

Despite the wide acceptance of the chronic noncommunicable disease model in modern medicine, there remains in our culture a sense that disorders with many causes have reduced legitimacy. Therefore, both clinicians and their patients would feel more secure if a large indisputable cause were found for their disorders. This, however, is a social and not a scientific problem. (p 1089-1090) [Emphasis added]

So a monocausal breakthrough would make clinicians and their patients feel more secure. So, telling a bereaved woman that her sadness is the expected and reasonable response to the death of her spouse will make her feel less secure than telling her the gross falsehood that there is something wrong with her brain. Or telling a battered wife that her sadness is the understandable response to the violence would make her feel less secure than telling her it stems from a brain disease. This is exculpation taken to a new level. We lie to our customers because it makes them feel more secure.

Dr. Kendler closes his essay on an upbeat, exhortative note.

The stigma of psychiatric illness and the low status of the psychiatric profession need to be addressed at both social and political levels and will not likely be solved through the discovery of major single causes for our illnesses. The legitimacy of the discipline of psychiatry does not rest on our ability to find single major causes of our disorders. (p 1090)

How does one address the stigma associated with psychiatric disorders and the low status of the psychiatric profession at social and political levels? PR campaigns? Lobbying politicians to pass psychiatry-friendly laws? These things are happening already, but the routine prescribing of pills and electric shocks continues to be psychiatrys only stock in trade, and the self-centered promotion of biological psychiatry continues to dominate the field.

Rather than grieving for the loss of our visions of another GPI around the corner, we can positively embrace the etiologic complexity of our disorders. (p 1090)

Actually they are not psychiatrists disorders. Rather, they are the disorders that psychiatrists self-servingly foist on their hapless clients.

If the common, morbid dysfunctions of the human cardiovascular, immune,hormonal, musculoskeletal, and gastrointestinal systems, which cause most of the morbidity in our country, are highly multifactorial, could we realistically expect anything else from the parallel dysfunctions of our mind/brain system? (p 1090)

In other words, psychiatric illnesses have as much ontological reality as diabetes, heart disease, cancers, hypertension, etc. Dr. Kendler encourages his colleagues not to grieve the abandonment of the quest, but rather to positively embrace the etiological complexity of psychiatric illnesses.

But what does etiologic complexity actually mean in this context, and why is it so important to Dr. Kendler?

Dr. Kendler uses various terms to describe etiologic complexity. For instance, he describes the illnesses in question as multifactorial, chronic noncommunicable, often associated with particular life styles, multicausal, etc.

Dr. Kendler has been working on this general theme for quite some time. In 2012 he published an article in Molecular Psychiatry calledLevels of explanation in psychiatric and substance use disorders: implications for the development of an etiologically based nosology (2012: 17, 11-21). Here are two quotes from the abstract:

The soft medical model for psychiatric illness, which was operationalized in DSM-III, defines psychiatric disorders as syndromes with shared symptoms, signs, course of illness and response to treatment. Many in our field want to move to a hard medical model based on etiological mechanisms. (p 11)

a move toward an etiologically based diagnostic system cannot assume that one level of explanation will stand out as the obvious candidate on which to base the nosology. This leaves two options. Either a hard medical model will be implemented that will require a consensus about a preferred level of explanation which must reflect value judgments as well as science. To take this approach, we need to agree on what we most want from our explanations. Alternatively, we will need to move away from the traditional hard medical model that requires that we ground our diagnoses in single biological essences, and focus instead on fuzzy, cross-level mechanisms, which may more realistically capture the true nature of psychiatric disorders. (p 11)

Theres a lot here. Firstly, there is what many readers might consider a contradiction in the first sentence: The soft medical model for psychiatric illness, which was operationalized in DSM-III, defines psychiatric disorders as syndromes [Emphases added] But syndromes are not illnesses. Heres how DSM-III defines a syndrome:

A grouping of symptoms that occur together and that constitute a recognizable condition. The term syndrome is less specific than disorder or disease. The term disease generally implies a specific etiology or pathophysiological process. In DSM-III most of the disorders are, in fact, syndromes. (p 368)

And elsewhere in the text (p 6), the term mental disorders is defined as a clinically significant behavioral or psychological syndrome. However, even before DSM-III was published (in 1980), it was widely accepted and promoted by psychiatrists that many psychiatric disorders, including depression, were genuine bona fide illnesses. (In my entire career I have encountered only one psychiatrist who acknowledged that psychiatric disorders were syndromes, not real illnesses.) This massive deception has been discussed at great length in various venues and need not be labored here. But what is noteworthy is Dr. Kendlers next sentence: Many in our field want to move to a hard medical model based on etiological mechanisms. But in fact almost all psychiatrists have already made this move and have been promoting the chemical imbalance hoax for decades. Many psychiatrists who are now retired practiced nothing but bio-bio-bio psychiatry for their entire careers.

Obviously Dr. Kendler is aware of this. So, what point is he making?

a move toward an etiologically based diagnostic system cannot assume that one level of explanation will stand out as the obvious candidate on which to base the nosology. (p 11)

In other words: if psychiatrists continue down their present road trying to use science to prove their various disease theories, they are just as likely to discover that major depression, schizophrenia, PTSD, etc., stem from psychosocial and economic causes rather than from their cherished brain diseases. In effect Dr. Kendler is saying: abandon the search or we run the risk of losing everything. (We) cannot assume that one level of explanation will stand out as the obvious candidate on which to base the nosology. In other words, we cannot assume that biological explanations will emerge as the dominant perspective. Dr. Kendler warns his colleagues, we need to agree on what we most want from our explanations. What does he mean by this? Read on.

Here are some quotes from the body of the 2012 article:

Let me sketch what we might find for MD [major depression]. Single gene effects for MD are even smaller and less well established than for AD [alcohol dependence]. Aggregate genetic effects are also somewhat weaker and are modified by a range of environmental exposures. Structural and functional magnetic resonance imaging studies have suggested a range of central nervous system abnormalities that correlate with MD but the specificity and strength of these associations, as well as their causal status, remain uncertain. A number of physiological abnormalities including endocrine and immune function have been reported in cases of MD but again, sensitivity and specificity have typically remained modest. Several aspects of personality are strongly correlated with risk for MDespecially neuroticism. This association is almost certainly causal but is nonspecific as high levels of neuroticism predispose to many internalizing disorders. Some cognitive processes may be more specific and here their causal role has been clearly demonstrated by many randomized controlled trials of cognitive behavior therapy. A range of early environmental risk factors have been well established for MD (for example, poor parenting and sexual abuse) and are generalizable across cultures but are quite nonspecific. Stressful life events can be quite strongly associated with risk for MD. Much, but not all, of this association is likely causal and some classes of events are moderately specific for MD. However, stressful life events are likely to be quite distal influences on risk pathways to MD and many such events predispose to other psychiatric disorders. Economic factors can impact on risk for MD via levels of unemployment and cultural factors can shape the expression and help-seeking behavior of those with depressive syndromes. (p 16)

Nature does not appear to have provided us one critical level of explanation for psychiatric illness that stands out from the background. For CF [cystic fibrosis], explanatory power is highly concentrated in the level of DNA base-pair variation. For psychiatric disorders, explanatory power is dispersed and diffuse. (p 16)

So, genuine scientific investigation might show that depression, say, is as likely to stem from sad events in peoples lives as from any kind of brain disease.

The current status of our science, and, most probably, the nature of psychiatric disorders themselves, does not yield up unambiguous choices for the best level at which to define psychiatric illness etiologically. (p 16) [Emphasis added]

Or might even show that depression is much more likely to stem from sad events.

But, despite these obvious concessions to a bio-psycho-social-cultural-economic perspective, Dr. Kendler is careful not to jettison the baby with the bathwater. He still seeks to preserve the notion that psychiatric disorders are real illnesses.

a rejection of the hard medical model for psychiatric disorders should not be misunderstood as setting up a deep divide between etiologic models for psychiatric and medical disorders. (p 16)

If, as our review of the data suggest, there is no a priori way to pick a single level of explanation on which to base an etiological nosology, we could try to argue it out on pragmatic grounds. What do we most want as a field from our explanations? (p 17)

What indeed? To date, psychiatrys primary motivations have been enhanced prestige, expansion of scope, and increased earning power, all of which were well-served by the chemical imbalance hoax.

What Dr. Kendler is telling his colleagues here is that the hoax is exposed; that science will not give them what they seek; and that by continuing to promote a purely biological perspective they are running the risk of losing what they want most: the reality of psychiatric illness. In other words, the science is not going our way, so we need to ask ourselves what do we most want, and then promote concepts that will help us achieve this. Dr. Kendlers wording is carefully chosen, but it seems to be that he is encouraging his colleagues to dispense with the formalities and neutrality of science and promote concepts that will retain psychiatrys hegemony in the field: what we want most.

Towards the end of the article Dr. Kendler provides us with more descriptors of the psychiatric diagnostic system that he envisions for the future. These include disorders (of) complex, mutually reinforcing networks of causal mechanisms, disordered multi-level mechanisms, and higher-order disturbances in multi-level mechanisms. [Emphases added]

Note the words disorders, disordered, and disturbances. Dr. Kendler, as in the 2019 paper, affords no recognition to the fact that the thoughts, feelings, and actions in question are not actually illnesses, and in many (perhaps most) cases are clearly adaptive.

Four years later (2016) Dr. Kendler published The Nature of Psychiatric Disorders (World Psychiatry, 2016: 15: 5-12). Heres a quote from the abstract:

Therefore, we should argue more confidently for the reality of broader constructs of psychiatric illness rather than our current diagnostic categories, which remain tentative. Finally, instead of thinking that our disorders are true because they correspond to clear entities in the world, we should consider a coherence theory of truth by which disorders become more true when they fit better into what else we know about the world. In our ongoing project to study and justify the nature of psychiatric disorders, we ought to be broadly pragmatic but not lose sight of an underlying commitment, despite the associated difficulties, to the reality of psychiatric illness. (p 5)

Note the phrase we ought to not lose sight of an underlying commitment, despite the associated difficulties, to the reality of psychiatric illness. To which I can only ask: why not? The common and accepted meaning of the word illness is something going significantly awry with the structure or function of an organ. If what psychiatrists call major depression doesnt actually conform to this description, why should psychiatry maintain an underlying commitment to the reality of psychiatric illness? Also, note the phrase In our ongoing project to study and justify the nature of psychiatric disorders [Emphasis added]. Isnt this arguably the very opposite of valid science? Didnt most of the great errors of science stem from efforts to justify the status quo often for the benefit of various powerful conflicting interests?

Despite Dr. Kendlers writings on these matters, his polycausal model is not attracting a large following. Here are quotes from the websites of some psychiatric facilities:

Harvard Medical School: What causes depression?

Certain areas of the brain help regulate mood. Researchers believe that more important than levels of specific brain chemicals nerve cell connections, nerve cell growth, and the functioning of nerve circuits have a major impact on depression. Still, their understanding of the neurological underpinnings of mood is incomplete. [Note how the simplistic chemical imbalance theory is being nudged aside, and being replaced by the more generic notion of nerve functioning.]

This quote is followed by five pages of closely-written type under the following headings: (Brain) regions that affect mood; Areas of the brain affected by depression (with picture); Nerve cell communication; How the (neurological) system works; When the (neurological) system falters; Kinds of neurotransmitters; How neurons communicate (with picture); Genes effect on mood and depression; Temperament shapes behavior; Stressful life events; How stress affects the body; Early losses and trauma; Seasonal affective disorder; Medical problems; and Depression medications.

The material is heavily slanted towards a biological perspective. Even the headings that sound psychosocial are slanted. The section on stressful life events contains:

Disturbances in hormonal systems, therefore, may well affect neurotransmitters, and vice versa.

The section on early losses and trauma contains:

Many researchers believe that early trauma causes subtle changes in brain function that account for symptoms of depression and anxiety. The key brain regions involved in the stress response may be altered at the chemical or cellular level.

Mayo Clinics article Depression (major depressive disorder) under the section Causes:

Its not known exactly what causes depression. As with many mental disorders, a variety of factors may be involved, such as:

Biological differences.People with depression appear to have physical changes in their brains. The significance of these changes is still uncertain, but may eventually help pinpoint causes.

Brain chemistry.Neurotransmitters are naturally occurring brain chemicals that likely play a role in depression. Recent research indicates that changes in the function and effect of these neurotransmitters and how they interact with neurocircuits involved in maintaining mood stability may play a significant role in depression and its treatment.

Hormones.Changes in the bodys balance of hormones may be involved in causing or triggering depression. Hormone changes can result with pregnancy and during the weeks or months after delivery (postpartum) and from thyroid problems, menopause or a number of other conditions.

Inherited traits.Depression is more common in people whose blood relatives also have this condition. Researchers are trying to find genes that may be involved in causing depression.

University of Rochester Medical Center, Major Depression, under the heading What causes depression?

Researchers are studying the causes of depression. Several factors seem to play a role. It may be caused by chemical changes in the brain. It also tends to run in families. Depression can be triggered by life events or certain illnesses. It can also develop without a clear trigger.

And so on. Its clear that most pro-psychiatry writers have received the message to downplay the simplistic too-little-serotonin-in-the-brain theory. Many, however, are still relying on this notion but couching it in different terms or adding some token psychosocial material, usually referred to as triggers.

In psychiatry there is no actual illness behind the symptoms. Major depressive disorder and psychiatrys other functional disorders are nothing more than loose collections of vaguely and arbitrarily defined thoughts, feelings, and behaviors. Psychiatrys clear objective in the past fifty years has been to pathologize every significant difficulty of thinking, feeling, and/or behaving, and to sell these bogus illnesses to the general public, the media, insurance companies, and government officials. The only essential difference between psychiatrists and street-corner drug-pushers is that the latter dont pretend that they are treating or curing illnesses.

Dr. Kendler has written an interesting and thought-provoking essay, but, in my view, has missed the central point: that depression, regardless of severity, duration, or impact, is not an illness. In fact, the opposite is the case. Depression is an adaptive mechanism that encourages us to make changes in our lives, habits, or circumstances. Just as pain provides an incentive to remove our hand from a hot stove, so depression encourages us to leave home, change jobs, develop some assertion skills, find a partner, etc. It is a mechanism that we share with virtually all other animal species, though the precise nature, complexity, and impact of the depression varies enormously.

As a species we can experience a wide range of emotions. We have this ability because we have machinery in our brains, and other organs, that enables this to happen. It is widely believed in psychiatric circles that if neurobiologists could uncover the precise mechanisms involved in experiencing depression, this would prove that depression is an illness. But, in fact, uncovering such mechanisms would no more pathologize depression than the neurobiology of walking or seeing or writing poetry would pathologize these activities. All human activity has a neurobiological underpinning, without which the activity cannot occur. We cannot see without eyes and optic nerves, etc.; we cannot feel without feeling machinery though we dont know exactly what this machinery is or how it works.

It certainly needs to be acknowledged that a persons feeling apparatus can malfunction, but such malfunctions are almost certainly rare, and cannot be routinely inferred from the presence of depression, regardless of severity. I have personally worked with hundreds of depressed individuals in my career, but have never encountered anyone whose level of depression was incommensurate with his/her story. Psychiatrists have essentially numbed themselves to this reality, firstly because of their spurious atheoretical approach (if youve got the symptomsregardless of why youve got themthen you have the illness); and secondly because their primary, or perhaps only, agenda is to clinch the diagnosis. It is particularly interesting in this regard that before the arrival of the pills, psychiatrists, most of whom practiced some kind of psychotherapy, had no difficulty recognizing the reality: that if people are given the opportunity to talk, they can tell you very clearly why they are depressed.

For several decades psychiatry has been lying to its customers that depression is a pathological state caused by a shortage of serotonin, and can, apparently miraculously, be diagnosed without ever examining the brain but simply by scoring yes on five of the nine items on the facile checklist. Some of the more prestigious facilities and colleges are stepping back from the serotonin hypothesis, largely as a result of being outed by the anti-psychiatry movement. But the diagnostic criteria are still the same, and the treatment hasnt changed. Its still eat these pills every day and come back in three months. And if that doesnt work, well try electric shocks.

Sometimes people feel trapped in their circumstances and are unable to muster the resources or skills to effect the necessary changes. An abused wife, for instance, might lack the economic or emotional means to leave her abusive husband. A man stuck in a job that he hates might not be able to see a way out. In cases like these, the depression can appear permanent and unrelenting. What people in these kinds of circumstances need is genuine help to identify the nature of the issues, generate positive targets, and begin the process of change. An abused wife needs a safe home for herself and her children, an effective safety network, and ongoing emotional and practical support. She does not need a diagnosis of major depressive disorder and a bottle of serotonin reuptake inhibitors.

Drugging a perfectly effective depression mechanism out of existence in order to reduce the immediate sense of discomfort and misery is a bit like sticking duct tape over the check engine light on ones dashboard. It may reduce ones negative feelings on the matter, but will produce no lasting benefits. Physicians who participate in these pharma-sponsored activities are not practicing medicine in any true sense of the term. Rather, they are drug pushers, pure and simple.

Dr. Kendler is proposing that psychiatry abandon the search for monocausal explanations of psychiatric illness and embrace the multicausal perspective. His reasoning is that this is a better perspective and is more in tune with present-day approaches to chronic non-communicable illnesses.

But he has perhaps revealed his true motivation in the 2016 paper:

In our ongoing project to study and justify the nature of psychiatric disorders, we ought to be broadly pragmatic but not lose sight of an underlying commitment, despite the associated difficulties, to the reality of psychiatric illness. (p 5)

In this very clear statement, Dr. Kendler is acknowledging an ongoing and underlying commitment to justify psychiatric disorders and to affirm their reality. But isnt this the very antithesis of science? Isnt it a fundamental requirement of science that we leave our beliefsno matter how deeply cherishedat the door, and go where the science takes us? How much credence should we afford a scholar who acknowledges, apparently without compunction, that in his work and writings his agenda includes an underlying commitment to the reality of psychiatric illness?

Read more from the original source:
The Chemical Imbalance Theory of Depression: Where Is It Going? - James Moore

Read More...

Using isotopes to reconstruct life histories within the transatlantic slave trade – UC Santa Cruz

February 18th, 2020 5:53 pm

"We know villages were destroyed and people were being taken," says Vicky Oelze. "We want to put numbers on it. I'm interested in individual histories." (Photo by Fred Deakin)

This geological map of equatorial Africa shows strontium isotope sampling locations Oelze's team will use to create the first-ever strontium isotope map of the region, a tool researchers will use to help trace the origins of Africans who were abducted during the transatlantic slave trade. (Map courtesy of Vicky Oelze)

Vicky Oelze, an assistant professor of anthropology, should introduce herself as a detective. Who else would attempt to fill in the gaps of the transatlantic slave trade by gathering clues from cemeteries in South Carolina and the shores of West Africa?

Four hundred years after the forced displacement of millions of Africans began, Oelze wants to use isotope biogeochemistry to trace back and identify the origins of individuals who were abducted and perished in the Americas.

Skeletal remains of slaves hold the clues that Oelze will use to identify where in Africa individuals were born and raisedinformation that has been lost to history.

"The narrative we have now is based on log books written by people who were deporting hundreds of Africans on ships," said Oelze. "They documented only the numbershow many left and how many arrived in the respective harbors. There was no recordkeeping of where people were actually from."

Archaeologists have had great success in parts of the developed Western world using strontium isotopes to identify the geological origin of prehistoric people, matching data to detailed strontium isotope maps researchers have developed. This type of map does not exist for tropical Africa, a gap Oelze will fill with over 400 environmental samples from 40 field sites that cover most major geological formations in tropical Africa. The principle is simple: Vegetation takes up a specific isotopic makeup of the trace element strontium from bedrock, and, in tiny quantities, that isotopic "signature" becomes locked in the teeth of people and animals that consume it. Oelze will use samples of African flora and fauna to build a strontium isotope map to match the signatures in skeletal remains of slaves to specific regions in Africa.

With support from the Helen and Will Webster Foundation, Oelze is hiring a postdoctoral researcher for two years to work in partnership with collaborators at the Max Planck Institute for Evolutionary Anthropology in Germany. In a second step, the team will start examining human remains from the Americas for their strontium isotope values. Strontium isotope analysis is particularly valuable when deterioration of skeletal material has ruled out genetic analyses as an option, and it is a much more precise way to assess human mobility on an individual, rather than population, level, said Oelze. The team will also analyze human remains from urban centers of the West African slave trade in collaboration with UCSC archaeologist Cameron Monroe.

"We know villages were destroyed and people were being taken," said Oelze. "We want to put numbers on it. I'm interested in individual histories."

The remains of millions of slaves are buried in designated slave cemeteries and near slave trade centers in the Caribbean and the Americas, as well as in informal burial plots that have been lost to history, noted Oelze. "It is imperative to include descendant communities in the process, she said. Many have a genuine interest in their ancestors. It's important to them, which is why so many are turning to 23andMe."

However, genetics from Africa are postcolonial and therefore flawed, said Oelze. As people were displaced by the pressures of slave raids, they effectively erased their geographic origins; strontium isotope analysis holds the promise of retracing movements from the past, she said.

Oelze's results will also aid wildlife conservation. "Trafficking of endangered animals is of growing concern to conservation, and this map of strontium isotopes in tropical Africa will help identify hotspots of illegal poaching activity," said Oelze, who plans to share her data internationally in open-access publications. She is also eager to use the findings to spark interest in STEM fields among students from Historically Black Colleges and from high schools with diverse student populations.

A hub of excellence

UC Santa Cruz has the potential to lead the field in tracing the histories, geographies, and molecular archaeology of the slave trade, according to Katharyne Mitchell, dean of the Division of Social Sciences. In Anthropology, Lars Fehren-Schmitz brings expertise in the analysis of ancient DNA, and Monroe has conducted extensive research in Bnin and Togo on the transformation of West African communities during the slave trade, as well as related archaeological research in the Caribbean. In History, Professor Greg O'Malley has done pathbreaking work on the transatlantic slave trade.

"This cohort of brilliant scholars is doing transformational work," said Mitchell. "Vicky is a powerhouse, and I'm delighted the Webster family wanted to support her research. I see great things emerging from this."

Oelze, who joined the faculty in 2016 from the Max Planck Institute for Evolutionary Anthropology, will organize a symposium on campus on the molecular forensics of the transatlantic slave trade, drawing historians, archaeologists, isotope geochemists, and geneticists to campus.

Read this article:
Using isotopes to reconstruct life histories within the transatlantic slave trade - UC Santa Cruz

Read More...

Transplanting the immune system: Easier on patients than medication? – WNDU-TV

February 18th, 2020 5:52 pm

There are nearly 35,000 organ transplants done in the U.S. every year. Once patients receive their transplant, they face a lifetime of medications that keep their body from rejecting the new organ, but those medications can cause serious side effects.

Now, a groundbreaking procedure has successfully changed that for one woman.

Having breakfast together was nearly impossible for Barb Okey and her husband after her kidney transplant. The 24 pills she took before breakfast ruined her appetite, and the side effects left her tired. But that's all in the past now.

In 27 years doing transplants, Dr. Dixon Kaufman has never done one like Barb's. Her sister's kidney was a perfect match, but then both women took part in a second pioneering transplant to give Barb her sister's immune system.

"We had the transplant and the next day I started radiation. I had to do radiation for 10 days," Barb recalled. "That was to suppress my immune system. After the 10th day, they gave me my sister's stem cells."

"The immune cells start to multiply, so she has not only the kidney from her sister but a little bit of her sister's immune system, and we call that phenomenon chimerism a,nd that's where you have a dual immune system," Kaufman said.

The immunity accepted the new kidney and left Barb drug-free.

"It's the start of hopefully a long progression of trials that will allow more and more people to, if not completely eliminate the medicines, significantly reduce them," Kaufman said.

"I feel very, very lucky. Very lucky," Barb said.

Barb is just the second person in the U.S. to take part in the national trial pioneering the duel transplant. The hope is that the procedure will one day be available to transplant recipients who are not perfect matches with their donors, and possibly even to those who have had transplants in the past.

MEDICAL BREAKTHROUGHSRESEARCH SUMMARYTOPIC: TRANSPLANTING THE IMMUNE SYSTEM: EASIER ON PATIENTS?REPORT: MB #4700

BACKGROUND: Organ transplantation is sometimes necessary when one of a patient's organs has failed. This can happen because of injury or illness. The organ may come from a living donor or one who has died. Transplants can include heart, intestine, kidney, liver, lung, or pancreas. Often patients must wait a long time for an organ transplant and doctors must match donors to recipients to reduce the risk of transplant rejection. (Source: https://medlineplus.gov/organtransplantation.html)

REJECTION RISK: The immune system usually protects you from substances that may be harmful, but it can also simply attack anything that enters the body, which the immune system detects as "foreign", and this includes transplanted organs. When a person receives an organ in transplant surgery, their immune system may recognize that it is foreign if the cells of the organ are different or "not matched". Mismatched organs can trigger a blood transfusion reaction or transplant rejection. To help prevent this rejection, doctors try their best to match similar proteins known as antigens between the donor and recipient. Tissue typing ensures the organ or tissue is as similar as possible to the recipient's tissue. The match is usually not perfect, as only identical twins have identical tissue antigens. Doctors use medicines to suppress the recipient's immune system with the goal of preventing it from attacking the newly transplanted organ. If these medicines are not used, the body will almost always launch an immune response and destroy the foreign tissue. Some exceptions include cornea transplants, because the cornea has no blood supply. Also, transplants from one identical twin to another are almost never rejected. (Source: https://medlineplus.gov/ency/article/000815.htm)

NEW RESEARCH: Medeor Therapeutics is now developing cell-based therapy to reprogram an organ recipient's immune system to accept the transplanted kidney without the need for long-term use of immune system suppressing drugs. The study is in Phase 3 and is working to demonstrate the efficacy and safety of how transplanting some of the stem cells from the organ donor into the organ recipient after transplant surgery could cause an immune tolerance; preserving the organ donation and preventing kidney transplant rejection. It would also eliminate the need for immunosuppressive drugs for the rest of the patient's life. (Source: https://clinicaltrials.gov/ct2/show/study/NCT03363945?show_locs=Y#locn)

See the article here:
Transplanting the immune system: Easier on patients than medication? - WNDU-TV

Read More...

MS: Dietary interventions may calm down the immune system – Medical News Today

February 18th, 2020 5:52 pm

A study in mice has shown that a change in diet may slow diseases that involve the activation of the immune system, such as multiple sclerosis (MS). Could the findings lead to improved treatments in humans?

In the United States, nearly 1 million people over the age of 18 are living with a diagnosis of MS, according to estimates.

MS is the most common of the inflammatory disorders with an autoimmune component, which refers to the immune system attacking and damaging healthy tissue.

In MS, the immune system attacks the myelin sheaths that protect the nerve cells in the brain and spinal cord, disrupting nerves messages to and from the brain.

The result can involve muscle weakness, numbness, trouble with balance and coordination, and cognitive decline, all of which get worse over time.

Doctors most frequently diagnose MS in young adults, although the diagnosis can be made at any age.

At present, no medical treatment can prevent or slow MS without greatly increasing the risk of infection or cancer. But what if dietary changes could delay the diseases onset and progression in high risk individuals?

Researchers have recently explored the role of methionine, an amino acid, in the overactive inflammatory response of conditions such as MS.

The teams results now appear in the journal Cell Metabolism.

While methionine is essential to a healthy immune system, it has an adverse effect on people at risk of autoimmune disease.

Russell Jones, Ph.D., of the Van Andel Institute, in Grand Rapids, Michigan, is the studys senior author. He comments on the findings, explaining:

Our results suggest [that] for people predisposed to inflammatory and autoimmune disorders like multiple sclerosis, reducing methionine intake can actually dampen the immune cells that cause disease, leading to better outcomes.

Many types of cell throughout the body produce methionine, a building block of protein and a form of fuel.

Defensive immune cells that respond to threats called T cells do not produce their own methionine and instead rely on dietary sources.

Certain animal products, such as meat and eggs, have especially high amounts of methionine.

One of the ways that the body defends itself against threats such as pathogens, or germs, is by flooding the affected area with T cells.

The researchers found that ingested methionine added fuel to this process by helping the T cells replicate and branch into specialized subtypes quicker.

However, once boosted by methionine, some of these reprogrammed T cells caused inflammation or swelling.

This is usually a healthy immune response, but if the swelling persists, it can cause damage such as that which characterizes MS.

The scientists found that dramatically lowering the amount of methionine in the diet of mice with induced MS changed the reprogramming of their T cells and limited the cells ability to cause swelling in the brain and spinal cord.

This, in turn, slowed the diseases progression.

These findings provide further basis for dietary interventions as future treatments for these disorders, Jones notes.

By restricting methionine in the diet, youre essentially removing the fuel for this overactive inflammatory response without compromising the rest of the immune system. Russell Jones, Ph.D.

However, before dietary guidelines can be established, researchers must prove that humans also experience these effects.

At present, there is no comprehensive understanding of the cause of MS, although genes related to the immune system play a role, as do environmental and metabolic factors, such as obesity.

The fact that metabolic factors like obesity increase the risk of developing multiple sclerosis makes the idea of dietary intervention to calm down the immune system particularly appealing, says co-author Catherine Larochelle, Ph.D., of the University of Montreal, in Canada.

The researchers will also investigate the possibility of creating new medications to target methionine metabolism.

The present study is only the latest to explore the role of dietary methionine limitation in disease treatment.

In 2019, a study from the Locasale Lab, at Duke University, in Durham, NC, showed that the cancer-fighting effects of chemotherapy and radiation could be improved by reducing methionine intake.

Link:
MS: Dietary interventions may calm down the immune system - Medical News Today

Read More...

New research: Vaping weakens fight against infections – Grand Forks Herald

February 18th, 2020 5:52 pm

SIOUX FALLS, S.D. E-cigarettes are often portrayed as safer than cigarettes. But a new study indicates the use of e-cigarettes, or vaping, makes it harder to fight infections whether or not the e-cigarette contains nicotine.

Vaping weakens cells in the body that are crucial to the fight against infections, according to the laboratory study by researchers at Veterans Affairs San Diego Healthcare System and the University of California San Diego, published earlier this month in the American Journal of Physiology-Cell Physiology.

The negative effect on the cells known as neutrophils, a type of white blood cell, was similar to that experienced when they are exposed to environmental toxins such as cigarette smoke, the researchers found in the study conducted on both humans and mice.

The study adds to the body of research showing that vaping's reputation as a safer alternative to smoking may be less true than many believe. Based on the findings, Dr. Laura E. Crotty Alexander of VA San Diego and University of California San Diego and the corresponding author on the paper, cautioned against using e-cigarettes.

We recommend that vaping be avoided in general, as our data and other findings demonstrate multiple possible adverse health effects caused by the use of e-cigarette and vaping devices," she said.

The research was conducted by exposing human neutrophil cells to e-cigarette vapor, a practice later confirmed on mice. It shows vaping limited neutrophils ability to get to the site of an infection, fight it once they arrived and produce compounds that fight bacteria.

Crotty Alexander said that based on the lab findings, it appears that the key chemicals that immune cells are exposed to during vaping cause dysfunction and thus weaken the immune system.

Further work by the researchers will focus on how the amount or style of vaping affects the immune system.

About 3% of American adults, approximately 7 million people, use e-cigarettes, according to a 2017 study. But youth and young adults are taking up the practice at a much higher rate, according to a 2016 U.S. Surgeon General report.

The emergence last year of a vaping related respiratory illness that sickened thousands and killed dozens drew a harsh spotlight to the potential risks of vaping.

Federal and state officials continue to investigate the illness, tentatively linked to the inclusion of vitamin E acetate within some e-cigarette fluids. Partly in response to the wave of illnesses, the Trump administration banned a range of vape liquid flavors and speedily approved legislation that raised the age of those allowed to buy both tobacco and vaping products that contain nicotine from 18 to 21.

Read more here:
New research: Vaping weakens fight against infections - Grand Forks Herald

Read More...

Patient health, flu myths, and signs of a strong immune system – Chiropractic Economics

February 18th, 2020 5:52 pm

Chiropractic Economics February 12, 2020

Health care experts in the wellness field are scrambling to keep patients well during a hard-hitting flu season and additional worries about a new coronavirus.

Keeping patients immune system in top shape with the signs of a strong immune system, experts say, is a way to combat both.

More than 12,000 adults and 78 children have died during this flu season according to the weekly flu report from the Centers for Disease Control and Prevention (CDC). While the coronavirus has dominated the headlines, the flu is much more likely to impact Americans and should be the main concern saysLibby Richards, an associate professor of nursing in PurduesSchool of Nursing.

Its important to keep in mind that while we currently do not have a vaccine for coronavirus, we do have a safe and effective vaccine for the flu, and its not too late to get one, Richards says. We are still in the peak of flu season, so vaccination is important to protect you and those around you. The flu vaccine helps protect not only you from influenza but can also lessen your chance of flu-related complications.

According to Purdue University doctors, adults and children need to be fever-free for 24 hours without the assistance of over-the-counter or prescription medications before they can return to work or school. Its also never too late to get a flu shot.

Eating right, maintaining a healthy lifestyle and getting enough sleep are some of the primary drivers of and signs of a strong immune system.

This season the CDC estimates that 9.7 million cases of the flu have been thus far diagnosed.

Also along the lines of creating or maintaining a healthy immune system for patients includes maintaining a healthy weight, eating plenty of fruits and vegetables, drinking plenty of fluids, meeting physical activity guidelines, not smoking, and limiting alcohol consumption and stress.

Seven to nine hours of sleep is recommended when you are feeling sick, as well as when you are healthy, Richards said. In addition to getting adequate sleep when ill, it is also important to rest during the day and try to avoid overexertion.

If you have a productive cough, do everyone a favor and avoid the gym. Staying home is a perfect way to not spread germs. If you have mild cold symptoms and you feel you have the energy to exercise, go for it as exercise might help you feel better, but consider reducing the duration or intensity of your exercise. If you are having fatigue, body aches, stomach issues, you should stay home and rest as exercise could increase your chance of an injury.

When it comes to children, Richards says, keep washing everyones hands.

Kids touch everything, which is one big way germs are spread, she says. Kids also tend not to understand or value what personal space is and can be in each others faces all the time. Parents, teachers and caregivers can demonstrate proper hand-washing and cough hygiene all year long not just during flu season[And] as much as we love to show affection with kisses, its possible to spread the flu one to three days prior to the start of symptoms.

The human immune system fights off infection, disease, viruses and more. But if the immune system protects you, why do you get sick?

The immune system (tonsils, lymph nodes, lymph vessels, thymus gland and bone marrow) consists of the lymphatic system, and your skin and mucus membranes act as the first line of defense, according to Roswell Park, the U.S.s first cancer center. The skin presents the physical barrier, while the mucus membranes that line your bodys openings make and release substances that repel invaders.

Vaccines work with your bodys natural defenses to create immunity to a specific disease, writes Roswell Park. Long ago, people realized that survivors of a disease didnt get that disease again. A British doctor is often credited with the first vaccine (for smallpox) in the 1790s, but a Chinese emperor who was a smallpox survivor himself started an inoculation program against the disease in the mid-1600s.

When someone with the flu coughs or sneezes, flu germs enter the air and are breathed in by other potential carriers. Will they get sick? What are their signs of a strong immune system? It depends on:

There still remains a common mis-perception among patients that they can get the flu by getting a flu shot. This myth leads to the spreading of the flu by un-vaccinated individuals.

The flu vaccine contains an inactive virus and gives the body a preview of what to look for and how to fight it off. Sometimes individuals can feel effects after a flu shot due to the body creating an immune response, as it should. Headaches or low-grade fevers are not out of the ordinary and are sometimes mistaken for the flu but are just natural responses from the body.

The flu season can go well into May, and individuals age 6 and up should get the flu shot which traditionally protects against influenza A (H1N1) and (H3N2), and the influenza B virus. For additional flu info from the CDC go to cdc.gov/flu/index.htm.

Read more from the original source:
Patient health, flu myths, and signs of a strong immune system - Chiropractic Economics

Read More...

How Patients Die After Contracting COVID-19, The New Coronavirus Disease : Goats and Soda – NPR

February 18th, 2020 5:52 pm

A doctor wearing a face mask looks at a CT image of a lung of a patient at a hospital in Wuhan, China. AFP via Getty Images hide caption

A doctor wearing a face mask looks at a CT image of a lung of a patient at a hospital in Wuhan, China.

More than 1,300 people, almost all in China, have now died from COVID-19 the newly minted name for the coronavirus disease first identified in Wuhan, China, that has infected more than 55,000 people.

Yet according to the World Health Organization, the disease is relatively mild in about 80% of cases, based on preliminary data from China.

What does mild mean?

And how does this disease turn fatal?

The first symptoms of COVID-19 are pretty common with respiratory illnesses fever, a dry cough and shortness of breath, says Dr. Carlos del Rio, a professor of medicine and global health at Emory University who has consulted with colleagues treating coronavirus patients in China and Germany. "Some people also get a headache, sore throat," he says. Fatigue has also been reported and less commonly, diarrhea. It may feel as if you have a cold. Or you may feel that flu-like feeling of being hit by a train.

Doctors say these patients with milder symptoms should check in with their physician to make sure their symptoms don't progress to something more serious, but they don't require major medical intervention.

But the new coronavirus attacks the lungs, and in about 20% of patients, infections can get more serious. As the virus enters lung cells, it starts to replicate, destroying the cells, explains Dr. Yoko Furuya, an infectious disease specialist at Columbia University Irving Medical Center.

"Because our body senses all of those viruses as basically foreign invaders, that triggers our immune system to sweep in and try to contain and control the virus and stop it from making more and more copies of itself," she says.

But Furuya says that this immune system response to this invader can also destroy lung tissue and cause inflammation. The end result can be pneumonia. That means the air sacs in the lungs become inflamed and filled with fluid, making it harder to breathe.

Del Rio says that these symptoms can also make it harder for the lungs to get oxygen to your blood, potentially triggering a cascade of problems. "The lack of oxygen leads to more inflammation, more problems in the body. Organs need oxygen to function, right? So when you don't have oxygen there, then your liver dies and your kidney dies," he says.

That's what seems to be happening in the most severe cases. About 3% to 5% of patients end up in intensive care, according to the WHO. And many hospitalized patients require supplemental oxygen. In extreme cases, they need mechanical ventilation including the use of a sophisticated technology known as ECMO (extracorporeal membrane oxygenation), which basically acts as the patient's lungs, adding oxygen to their blood and removing carbon dioxide. The technology "allows us to save more severe patients," Dr. Sylvie Briand, director of the WHO's pandemic and epidemic diseases department, said at a press conference Monday.

Many of the more serious cases have been in people who are middle-aged and elderly Furuya notes that our immune system gets weaker as we age. She says for long-term smokers, it could be even worse because their airways and lungs are more vulnerable. People with other underlying medical conditions, such as heart disease, diabetes or chronic lung disease, have also proved most vulnerable. Furuya says those kinds of conditions can make it harder for the body to recover from infections.

"Of course, you have outliers people who are young and otherwise previously healthy who are dying," Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, recently told NPR's 1A show. "But if you look at the vast majority of the people who have serious disease and who will ultimately die, they are in that group that are either elderly and/or have underlying conditions."

The WHO has said most deaths so far appear to be from multi-organ failure and has calculated the case fatality rate at about 2% or less, based on earlier data from China. However, infectious disease experts note that it's hard to know the true numbers at this point in the epidemic.

But del Rio notes that it's not just COVID-19 that can bring on multi-organ failure. Just last month, he saw the same thing in a previously healthy flu patient in the U.S. who had not gotten a flu shot.

"He went in to a doctor. They said, 'You have the flu don't worry.' He went home. Two days later, he was in the ER. Five days later, he was very sick and in the ICU" with organ failure, del Rio says. While it's possible for patients who reach this stage to survive, recovery can take many weeks or months.

In fact, many infectious disease experts have been making comparisons between this new coronavirus and the flu and common cold, because it appears to be highly transmissible.

"What this is acting like it's spreading much more rapidly than SARS [severe acute respiratory syndrome], the other coronavirus, but the fatality rate is much less," Fauci told 1A. "It's acting much more like a really bad influenza."

What experts fear is that, like the flu, COVID-19 will keep coming back year after year.

Originally posted here:
How Patients Die After Contracting COVID-19, The New Coronavirus Disease : Goats and Soda - NPR

Read More...

Fight the cold with immunity-boosting cocktail – KTNV Las Vegas

February 18th, 2020 5:52 pm

LAS VEGAS (KTNV) Many people are fighting the flu with a cocktail.

The Myers Cocktail is an unconventional way to boost your immune system and it's becoming more popular in Las Vegas.

The cocktail consists of a combination of vitamins and minerals, including magnesium, calcium, vitamins B and C, and then it is slowly pushed into your body by an IV.

RELATED: What to know about the 2019-2020 flu season

This season, Las Vegas Dr. Julio Garcia says they've seen an uptick in the number of patients asking for a Myers Cocktail versus the flu shot because it works faster.

Garcia says the cocktail isn't the answer for every sickness and you should still go see a doctor regularly.

Here's more about the Myer's Cocktail from Trim Body M.D.

MYERS COCKTAIL1. An excellent option for IV hydration2. Contains IV fluid, glutathione, Vitamin C, Magnesium, 6 different B vitamins3. Helps energize the body4. Fights infection, cold, flu and fatigue

The Myers cocktail is a vitamin and mineral cocktail invented by Dr. John Myers, a physician from Baltimore, Maryland, who pioneered the use of intravenous vitamins and minerals as part of the overall treatment of various medical problems. Dr. Myers formula contains the following nutrients: magnesium, calcium B12, B6, B5, B complex and vitamin C. We have found it effective in relieving acute asthmatic attacks, migraines, autoimmune disorders, chronic fatigue syndrome, fibromyalgia, depression, cardiovascular diseases (angina and arrythmias), hay fever symptoms, cold and flu and even narcotic withdrawal. It is administered intravenously and promoted as an alternative treatment for a broad range of conditions. The Cocktail is given by a slow IV push or slow infusion to achieve concentrations of nutrients that are not obtainable with oral administration.

The Myers cocktail, along with IV fluids, is a very fast way to get critical vitamins, minerals, and hydration into your body. Many people live hectic, busy lives and have difficulty getting enough vitamins in their diet. There is no better way to replenish your vitamin stores than the intravenous route.

View post:
Fight the cold with immunity-boosting cocktail - KTNV Las Vegas

Read More...

Early Infections Don’t Seem to Prevent Allergies – But Getting Dirty in Nature Might – ScienceAlert

February 18th, 2020 5:52 pm

Over the past few decades, allergies and asthma have become common childhood diseases, especially in developed countries. Almost 20 percent of Australians experience some kind of allergy, whether it's to food, pollen, dust, housemites, mould or animals.

When people suffer from food allergies, hay fever or asthma, their immune system incorrectly believes the trigger substances are harmful and mounts a defence.

The response can range from mild symptoms, such as sneezing and a blocked nose (in the case of hay fever), to anaphylaxis (from severe food allergies or bee stings) and asthma attacks.

We used to think the rise in allergic conditions was because we weren't exposed to as many early infections as previous generations. But the science suggests that's not the case.

However it seems being out in nature, and exposed to diverse (but not disease-causing) bacteria, fungi and other microorganisms may help protect against asthma and allergies.

In 1989, researcher David Strachan examined allergy patterns in more than 17,000 children in England. He noticed young siblings in large families were less likely to have hay fever than older siblings or children from small families.

He proposed that these younger siblings were exposed to more childhood illness at a younger age, as more bugs were circulating in these large families and the younger children were less likely to wash their hands and practise good hygiene.

Greater exposure to these childhood infections helped "train" their immune systems not to overreact to harmless things like pollen.

Strachan coined the term "hygiene hypothesis" to explain this phenomenon, and the idea has been appealing to our dirty side ever since.

Strachan wasn't the first to notice exposure to "dirty environments" seemed to prevent allergic disease. A century earlier, in 1873, Charles Blackley noted hay fever was a disease of the "educated class", and rarely occurred in farmers or people living in less sanitary conditions.

However, Blackley and Strachan were wrong about one important thing: the association between sanitation and allergies is not due to reduced exposure to early childhood infections (or "pathogens").

Large studies from Denmark, Finland, and the United Kingdom have found no association between the number of viral infections during childhood and allergic disease. In other words, exposure to disease-causing pathogens doesn't appear to prevent allergies.

In fact, exposure to childhood viral infections, in addition to making a child sick, may contribute to the development of asthma in predisposed children.

Many researchers now argue the term "hygiene hypothesis" is not only inaccurate but potentially dangerous, because it suggests avoiding infection is a bad thing. It's not.

Good hygiene practices, such as hand washing, are critical for reducing the spread of infectious and potentially deadly diseases such as influenza and the Wuhan coronavirus.

For healthy immune function, we need exposure to a diverse range of bacteria, fungi and other bugs known as microbes in the environment that don't make us sick.

Within urban environments, recent research shows people who live closer to green, biodiverse ecosystems tend to be healthier, with less high blood pressure and lower rates of diabetes and premature death, among other things.

More specifically, research has found growing up on a farm or near forests, with exposure to more biodiverse ecosystems, reduces the likelihood of developing asthma and other allergies.

This is potentially because exposure to a diversity of organisms, with a lower proportion of human pathogens, has "trained" the immune system not to overreact to harmless proteins in pollen, peanuts and other allergy triggers.

We can try to expose children to environments more like the ones in which humans, and our immune systems, evolved.

Most obviously, children need to have exposure to green space. Playing outdoors, having a garden, or living near green space (especially near a diverse range of native flowering plants) is likely to expose them to more diverse microbes and provide greater protection from allergic diseases.

Infants who are breastfed tend to have more diverse gut microbiomes (a larger variety of bacteria, fungi and other microscopic organisms that live in the gut), which makes them less likely to develop allergic diseases in childhood.

Having a varied diet that includes fresh and fermented foods can help cultivate a healthy gut microbiome and reduce allergic disease. As can using antibiotics only when necessary, as they kill off good bacteria as well as the bad.

So keep washing your hands, especially in cities and airports, but don't be afraid of getting a little dirty in biodiverse environments.

This article was co-authored by Chris Skelly, International Programme Director, Healthy Urban Microbiomes Initiative and Head of Programmes (Research and Intelligence), Public Health Dorset.

Emily Johnston Flies, Postdoctoral Research Fellow (U.Tasmania), University of Tasmania and Philip Weinstein, Professorial Research Fellow, University of Adelaide.

This article is republished from The Conversation under a Creative Commons license. Read the original article.

Read more here:
Early Infections Don't Seem to Prevent Allergies - But Getting Dirty in Nature Might - ScienceAlert

Read More...

NIH study supports new approach for treating cerebral malaria – National Institutes of Health

February 18th, 2020 5:52 pm

News Release

Tuesday, February 18, 2020

Findings suggest drugs targeting immune cells may help treat deadly disease mainly affecting children.

Researchers at the National Institutes of Health found evidence that specific immune cells may play a key role in the devastating effects of cerebral malaria, a severe form of malaria that mainly affects young children. The results, published in the Journal of Clinical Investigation, suggest that drugs targeting T cells may be effective in treating the disease. The study was supported by the NIH Intramural Research Program.

This is the first study showing that T cells target blood vessels in brains of children with cerebral malaria, said Dorian McGavern, Ph.D., chief of the Viral Immunology and Intravital Imaging Section at the NIHs National Institute of Neurological Disorders and Stroke (NINDS) who co-directed the study with Susan Pierce, Ph.D., chief of the Laboratory of Immunogenetics at the National Institute of Allergy and Infectious Diseases (NIAID). These findings build a bridge between mouse and human cerebral malaria studies by implicating T cells in the development of disease pathology in children. It is well established that T cells cause the brain vasculature injury associated with cerebral malaria in mice, but this was not known in humans.

More than 200 million people worldwide are infected annually with mosquito-borne parasites that cause malaria. In a subset of those patients, mainly young children, the parasites accumulate in brain blood vessels causing cerebral malaria, which leads to increased brain pressure from swelling. Even with available treatment, cerebral malaria still kills up to 25% of those affected resulting in nearly 400,000 deaths annually. Children who survive the infection will often have long-lasting neurological problems such as cognitive impairment.

The researchers, led by Drs. Pierce and McGavern, examined brain tissue from 23 children who died of cerebral malaria and 11 children who died from other causes. The scientists used state-of-the-art microscopy to explore the presence of cytotoxic lymphocytes (CTLs) in the brain tissue samples. CTLs are a type of T cell in our immune system that is responsible for controlling infections throughout the body.

Current treatment strategies for cerebral malaria focus on red blood cells, which are thought to clog blood vessels and create potentially fatal blockages leading to extreme pressure in the brain. However, findings in the mouse model demonstrated that CTLs damage blood vessels, leading to brain swelling and death. The role of CTLs in cerebral malaria in children hasnt been thoroughly investigated prior to this study.

The results of the current study demonstrate an increased accumulation of CTLs along the walls of brain blood vessel in the cerebral malaria tissue samples compared to non-cerebral malaria cases. In addition, the CTLs were shown to contain and release effector molecules, which damage cells, suggesting that CTLs play a critical role in cerebral malaria by damaging the walls of brain blood vessels.

The disease appears to be an immunological accident in which the CTLs are trying to control a parasitic infection but end up injuring brain blood vessels in the process, said Dr. McGavern.

In separate studies we discovered that treatment of mice with a drug that targets T cells rescued over 60% of otherwise fatal cases of experimental cerebral malaria, said Dr. Pierce. Given our findings of T cells in the brain vasculature of children who died of the disease, we are excited by the possibility that this drug may be the first therapy for cerebral malaria.

The impact of HIV coinfection on the risk of developing cerebral malaria is not known. The NIH researchers compared CTL patterns in the cerebral malaria cases that were co-infected with HIV and those that were HIV negative. In the HIV-negative cases, the CTLs were seen lining up against the inside wall of brain blood vessels. In the HIV-positive cases, the CTLs had migrated across the surface to the outside of the vessels. There were also significantly more CTLs present in the HIV-positive cases.

Together these findings suggest that CTLs may play an important role in cerebral malaria and that HIV infection may worsen the disease.

Additional research is needed to uncover the role of T cells in human cerebral malaria. Future studies will also investigate how targeting T cells may help treat the disease. Plans for a clinical trial are underway to test the effects of a specific T cell blocker in cerebral malaria patients in Malawi.

The NINDSis the nations leading funder of research on the brain and nervous system.The mission of NINDS is to seek fundamental knowledge about the brain and nervous system and to use that knowledge to reduce the burden of neurological disease.

NIAID conducts and supports research at NIH, throughout the United States, and worldwide to study the causes of infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses. News releases, fact sheets and other NIAID-related materials are available on the NIAID website.

About the National Institutes of Health (NIH):NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit http://www.nih.gov.

NIHTurning Discovery Into Health

Riggle et al. CD8+T cells target cerebrovasculature in children with cerebral malaria. Journal of Clinical Investigation.

###

Follow this link:
NIH study supports new approach for treating cerebral malaria - National Institutes of Health

Read More...

Laura’s Organic Elderberry And Gummies Are A Natural Way To Improve Health – Osprey Observer

February 18th, 2020 5:52 pm

During this time of year, we get our flu shots, but we also look for ways to improve our immune system. A healthy, natural option to improve your immune system are elderberries.

Valrico resident and mom of two little girls Laura DiSalvo believes in the health benefits of elderberries so much that she created a line of organic elderberry syrups and gummies.

I have a degree in biology and a Master in Biotechnology Business Management, DiSalvo said. In the beginning of my working years, before I stopped to stay at home with my girls, I worked in a military lab, working on various contracts. Ive been making elderberry syrup and gummies for over four years now after trying the store-made ones from different stores. We were hooked on elderberries, but the price for such a small bottle for all of us and how thick it was, I found myself looking for other options. I found a few people who sold it homemade, but I was not impressed. One was either too watery or another didnt taste right, so I decided I was going to make my own, and here we are.

And so, Lauras Organic Elderberry and Gummies was born.

According to WebMD, The berries and flowers of elderberries are packed with antioxidants and vitamins that may boost your immune system. They can help tame inflammation, lessen stress and help protect your heart too. They can also be a treatment for constipation, joint and muscle aches, headaches, kidney problems, minor skin conditions, stress and fevers.

What makes DiSalvos elderberry syrup and gummies different from store-bought versions is that she makes each batch small enough that she can monitor the temperature so she never overcooks or de-natures her berries.

The inside of the berries is the true medicine, DiSalvo said. If youre getting elderberry from someone and they are not squishing the berries after cooking, youre not getting the true benefit. Its a long process, time-consuming and messy, so most other makers may skip this part. I love it, though. I strain two times with cheesecloths to ensure it is smooth. I add local raw honey only when it is cooled down to ensure I will not denature my honey. I also only use organic, pesticide-free elderberry.

Her local raw honey comes from Andersens Apiary in Riverview.

To learn more about Lauras Organic Elderberry and Gummies, visit http://www.facebook.com/LaurasElderberry or email lauraselderberry@yahoo.com. Her elderberry syrup costs $20 for a 12 oz. jar and her gummies cost $20 for 120 gummies.

Link:
Laura's Organic Elderberry And Gummies Are A Natural Way To Improve Health - Osprey Observer

Read More...

Keto Diet and IBS: Can This Diet Help Treat Symptoms? – Healthline

February 18th, 2020 5:52 pm

If you deal with irritable bowel syndrome (IBS), youre not alone. This common condition causes bloating, gas, stomach pain, constipation, and diarrhea.

To manage IBS, your healthcare provider may recommend that you change your diet, improve your lifestyle quality, and limit your intake of certain fermentable carbs called FODMAPs.

You may have also heard that the high fat, very low carb ketogenic helps treat IBS symptoms.

Yet, you may wonder whether this claim is backed by scientific evidence and whether you should try out keto if you have IBS.

This article examines how the keto diet affects IBS symptoms.

Irritable bowel syndrome (IBS) affects 14% percent of the worlds population. Its symptoms include stomach pain, bloating, cramping, constipation, and diarrhea (1, 2).

Theres no one identifiable cause of IBS. Instead, it likely involves a number of processes that may be unique to each individual (1).

Possible causes include increased digestive sensitivity, chemical signals from your gut to your nervous system, psychological and social stress, immune system activity, changes in your gut bacteria, genetics, diet, infections, certain drugs, and antibiotic use (1, 3).

IBS treatment focuses on managing symptoms via medications, diet, and lifestyle adjustments (1, 4).

Many individuals find that food is a trigger for specific symptoms, so 7090% of people with IBS limit certain foods to try to decrease negative effects (1, 5).

Experts often recommend a diet that includes regular meals, as well as adequate fiber and fluids. You should limit alcohol, caffeine, and spicy or fatty foods if they trigger symptoms (5).

Currently, a common treatment for IBS is a low FODMAP diet, which limits short-chain, fermentable carbs that are poorly absorbed by your body. FODMAPs are found in wheat, onions, some dairy, and some fruits and vegetables (1, 6).

These carbs cause increased water secretion and fermentation in your gut, which produces gas. Although this doesnt negatively affect healthy people, it may trigger symptoms in people with IBS (1).

Diets low in FODMAPs have been shown to reduce the severity of IBS symptoms, particularly pain and bloating (2, 5, 7).

Very low carb, gluten-free, paleo, and immune-modulating diets are likewise used to treat IBS, though evidence on their effectiveness is mixed (2).

IBS is a chronic condition characterized by stomach pain, bloating, cramping, constipation, and diarrhea. Its commonly treated by restricting certain foods, eating a low FODMAP diet, and adopting other dietary and lifestyle changes.

The ketogenic diet is a high fat, low carb eating pattern thats similar to the Atkins diet. Originally developed in the 1920s to treat children with severe epilepsy, its commonly used for weight loss and other health conditions like blood sugar control (6, 8, 9, 10, 11, 12).

Its exact macronutrient ratio may differ based on individual needs, but its usually 75% fat, 20% protein, and 5% carbs (6, 13).

Keto limits bread, pasta, grains, beans, legumes, alcohol, sugar, and starchy fruits and vegetables while increasing your intake of high fat foods like nuts, seeds, oils, cream, cheese, meat, fatty fish, eggs, and avocados (6).

By restricting carbs to 50 grams or fewer per day, you enter a metabolic state in which your body burns fat for energy instead of carbs. This is known as ketosis (13, 14).

The keto diet is a low carb, high fat eating pattern that shifts your bodys metabolism away from carbs. Its long been used to treat epilepsy and other ailments.

Despite ketos popularity, very few studies investigate its effectiveness for treating IBS.

A 4-week study in 13 people with diarrhea-predominant IBS found that the keto diet helped reduce pain and improve the frequency and consistency of stools (15).

This may be due to the diets influences on your gut microbiome, or the collection of bacteria in your gut. Interestingly, people with IBS often have an imbalance in their types and numbers of gut bacteria, which may contribute to symptoms (16, 17).

Furthermore, animal and human studies reveal that very low carb diets deplete the bacteria in your gut that produce energy from carbs while boosting the number of beneficial bacteria (16, 18).

However, some research also suggests that low carb diets like keto decrease the overall diversity of gut bacteria and increase the number of inflammatory bacteria, which may have negative effects (18).

Currently, theres not enough information to conclude whether the keto diet can benefit people with IBS. Further studies are necessary.

Some research indicates that the keto diet may reduce symptoms of diarrhea-predominant IBS and improve aspects of your gut microbiome. Still, results are mixed and more research is needed.

Despite some promising results, evidence for using keto to treat IBS remains limited.

Its unclear whether positive effects can be attributed to the diet itself or rather the incidental elimination of trigger foods, such as FODMAPs or gluten (19).

Therefore, people with IBS shouldnt use the keto diet as a primary treatment for IBS.

Many people may find keto too restrictive in nature, as it eliminates food groups like grains, beans, and legumes.

That said, if this diet can fit into your lifestyle, and you are interested in how it could change your symptoms, please talk to a medical professional to learn more.

The keto diet isnt currently recommended as a standard treatment for IBS due to a lack of scientific evidence. Yet, if it fits your lifestyle, it may reduce some symptoms and provide other benefits. Speak to a medical professional if you want to learn more.

Its important to remember that the keto diet may have a few downsides.

For example, fatty foods trigger symptoms in some people with IBS. Because the keto diet is very high in fat, it may worsen symptoms instead of improving them (5).

Furthermore, the keto diet can be low in soluble fiber, a nutrient that may alleviate some IBS symptoms (20).

Thus, its important to eat plenty of leafy green vegetables and seeds to boost your intake of soluble fiber if you have IBS and decide to try keto. Alternatively, you can take a fiber supplement (5).

Finally, people with diabetes should consult a health professional before starting keto, as the low carb intake could cause dangerously low blood sugar levels (13).

The keto diets high fat levels may trigger IBS symptoms in some people. Furthermore, this eating pattern can be low in soluble fiber, a nutrient that may ease IBS-related complaints.

Studies on the ketogenic diet and IBS are limited and provide mixed results.

On the one hand, research demonstrates an improvement in diarrhea symptoms in people with IBS, as well as some positive changes to the gut microbiome.

On the other hand, keto may have several negative effects on your gut microbiome and is more restrictive than other dietary treatments.

Although the keto diet isnt currently recommended to treat IBS, some people may find it advantageous for symptom management or other benefits, such as weight loss and improved blood sugar control.

If youre curious about trying keto to help treat your IBS symptoms, its best to discuss your plans with your healthcare provider first.

View original post here:
Keto Diet and IBS: Can This Diet Help Treat Symptoms? - Healthline

Read More...

A Rare Human Disease Has Been Found in Dinosaur Bones, Could it Lead to a Treatment? – PharmaLive

February 18th, 2020 5:52 pm

It is largely accepted that the dinosaurs were killed off due to an asteroid impact on the planets surface that created a chain reaction of climactic calamities at least, thats the primary theory. And while all that is left of dinosaurs are their bones, those fossilized pieces can still provide us with important scientific resources, including perhaps a key to at least one rare disease.

Researchers have discovered the remains of a dinosaur from what is now modern Alberta, Canada that contains evidence of having suffered a condition similar to a rare cancer of the bone marrow. In bone remains from a hadrosaur, a duck-billed dinosaur, researchers found lesions in tail vertebrae bones that are similar to the rare disease Langerhans cell histiocytosis (LCH), a type of cancer that begins in the bone marrow. Details of the study were published in Nature.

According to the Cleveland Clinic, LCH, previously known as histiocytosis X, is characterized by abnormal increases in white blood cells called histiocytes. The histiocyte cells help the bodys immune system fight infection and destroy foreign materials. The extra immune cells produced by this condition may form tumors, which can affect parts of the body like the bones and possibly spread to other areas, the clinic said on its website. It typically affects children between the ages of five and 10 years. There are less than 200,000 diagnoses annually. The most common form of LCH is eosinophilic granuloma. Most patients afflicted with LCH tend to recover, but the condition can cause pain and swelling.

Langerhans cell histiocytosis historically was thought of as a cancer-like condition, but more recently researchers have begun to consider it an autoimmune phenomenon in which immune cells begin to overproduce and attack the body instead of fighting infection. In most cases it is not known why the disorder appears, although there may be a genetic link, the Cleveland Clinic said on its website.

Reimar / Shutterstock

Because of the different ways in which LCH can affect the body, there are different treatment options for people diagnosed with the disorder. In addition to steroid treatments, surgery and anti-inflammatory treatments can be recommended. Radiation treatment and chemotherapy can be used in some patients, the Histiocytosis Association noted on its website.

After a detailed study of the lesions in the hadrosaurs bones, the researchers confirmed that the issue afflicting the dinosaur was LCH. The researchers confirmed the diagnosis through macroscopic and microscopic analyses of the hadrosaur vertebrae and then compared to human LCH, as well as other pathologies. The hadrosaur pathology findings were indistinguishable from those of humans with LCH, supporting that diagnosis, the researchers said in their study abstract. The disease has been found in other animals, but this was the first time it was seen in a creature that died out millions of years ago.

Knowing that the disease has been discovered in dinosaurs could help lead to breakthroughs in potential treatments for the disease. Israel Hershkovitz, a palaeopathologist from Tel Aviv University who assisted in the study, told Science Alert that the goal of these kinds of studies, looking at disease states in long-dead creatures, could lead to an understanding of the causes of LCH and other diseases.

Ultimately, the goal of such studies is to understand the real cause of these illnesses and what evolutionary mechanisms allowed them to develop and survive, Hershkovitz told the publication. Perhaps if we understand a diseases underlying mechanisms we can treat its causes more effectively, instead of focusing on the symptoms, as modern medicine tends to do.

Continue reading here:
A Rare Human Disease Has Been Found in Dinosaur Bones, Could it Lead to a Treatment? - PharmaLive

Read More...

Synedgen to Present Data on Therapeutic for Ocular Mustard Gas Injury at NIH-Organized Medical Countermeasures Meeting – BioSpace

February 18th, 2020 5:52 pm

Feb. 18, 2020 19:00 UTC

- First results from ocular injury program to treat damage from sulfur mustard gas -

- Announces $1 million funding from the National Eye Institute for continuation of program development -

CLAREMONT, Calif.--(BUSINESS WIRE)-- Synedgen, a biotechnology company using glycochemistry to develop drugs that enhance and mimic the innate immune system, today announced a poster presentation at the upcoming National Institutes of Health (NIH)-organized scientific meeting, Developing Medical Countermeasures To Treat the Acute and Chronic Effects of Ocular Chemical Toxicity. The meeting will take place in Rockville, Maryland, on February 25-26, 2020.

Poster Presentation:

Title: Improving Corneal Wound Healing After Chemical Injury With Novel Therapeutic Glycopolymers

Presenter: Shenda Baker, Ph.D.

Date: Tuesday, February 25, 2020

Time: 2:00 p.m. - 3:00 p.m. ET

Location: National Institute of Allergy and Infectious Diseases (NIAID/NIH) Conference Center, 5601 Fishers Lane, Rockville, Maryland 20852

Were excited to share this promising data from Synedgens ophthalmic glycopolymer candidates, given the lack of effective drugs for this type of damage to the eye, said Dr. Brian Gilger, study lead and Professor of Ophthalmology at North Carolina State University College of Veterinary Medicine. Importantly, the new molecules from Synedgens glycopolymer platform have the potential not only to provide a powerful countermeasures solution, but also to be applied in the civilian market where corneal damage is a frequent cause of vision loss.

Sulfur Mustard (SM) is employed as a chemical weapon, and its increasing production and use in unstable regions throughout the world heightens the risk that it could be used in a terrorist attack against U.S. civilians or armed forces, potentially causing severe burns to the eyes, skin and respiratory tract. The ocular surface is uniquely susceptible to SM, resulting in corneal lesions, edema, ulceration, neovascularization and vision loss. There are currently no FDA-approved drugs for SM-induced ocular injuries to improve healing and reduce vision loss.

Synedgen has developed a class of glycopolymers with the ability to suppress inflammation, reduce infection, and improve healing at mucosal surfaces. One such glycopolymer reduces epithelial damage and inflammation in an animal model of potassium hydroxide (KOH)-induced ocular injury. This glycopolymer was well-tolerated, with reduced initial ocular inflammation (measured by Hackett-McDonald ocular scores) at 12 hours, and lower subsequent cumulative ocular inflammation. Furthermore, relative to control, the treatment prevented significant secondary ulceration, improved the healing rate and reduced corneal fibrosis. Given these results, preliminary optimization of five related compounds has been initiated in order to optimize the therapeutic efficacy of lead molecules against SM burns. This program is being funded by a three-year $970,000 award from the National Eye Institute (NEI/NIH) and the NIH Office of the Director (OD). The award is specifically earmarked for the Identification of lead compounds to topically treat sulfur mustard injury to reduce ocular damage and improve vision.

About Award

Research reported was supported by the National Eye Institute (NEI/NIH) and the NIH Office of the Director (OD) under Award Number U01EY030406. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

About Synedgen

Synedgen is a biotechnology company using glycochemistry to develop drugs that enhance and mimic the innate immune system. The companys lead development candidate is SYGN305 for gastrointestinal mucositis, where a large unmet need exists to prevent intestinal radiation injury, the single most important dose-limiting factor in cancer radiotherapy. Synedgens glycochemistry platform has already generated five FDA 510(k)-cleared therapeutics, one OTC drug, one veterinary indexed drug, and an out-licensed Phase 2 program, to Synspira, for the potential treatment of pulmonary complications of cystic fibrosis. Synedgen has research and manufacturing facilities in Claremont, California. For more information please visit http://www.synedgen.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200218005740/en/

Original post:
Synedgen to Present Data on Therapeutic for Ocular Mustard Gas Injury at NIH-Organized Medical Countermeasures Meeting - BioSpace

Read More...

Wisconsin Assembly to vote on bills fighting water pollution – WSAW

February 18th, 2020 5:52 pm

MADISON, Wis. (AP) A bipartisan, $10 million package of more than a dozen bills designed to combat groundwater contamination in Wisconsin is slated for approval in the state Assembly on Tuesday.

The bills contain the recommendations from a water quality task force called by Assembly Speaker Robin Vos to address growing concerns about groundwater contamination in the state. There is increased tension between environmentalists and farmers over the contamination of wells, the spreading of manure, the growth of large animal confinement facilities and the use of fertilizers.

The measures up for approval Tuesday tackle the issue from several angles, including expanding conservation efforts, bolstering research and education efforts, and improving state laws and regulations.

Democrats generally support the plan, but argue Republicans arent doing enough to stop the groundwater pollution. More needs to be done to prevent contamination as well as cleaning up pollution, said Democratic state Rep. Chris Taylor, of Madison, during debate of the bills in the Legislatures budget committee last week.

We have got to be much more aggressive, Taylor said. Weve got to stop the manure from running into peoples water in the first place and that is where (Republicans) have failed.

She called the proposals little baby steps.

Republican Rep. Amy Loudenbeck, of Clinton, said the bills are a good start and more would be coming.

The proposals would create a new water policy office; increase the number of county conservation workers; increase grants for owners of wells contaminated with manure or fertilizer to rebuild or replace them; increase money to study water quality issues; add a state agriculture staff member focused on grazing techniques for livestock to allow grasses to replenish; and make grants available for farmers who grow crops that require less fertilizer.

Once approved by the Assembly, the bills will go to the Senate where its unclear how much support there is. Time is running out for the Senate to act. It was expected to be in session Wednesday and then just one day in March before adjourning for the session.

Any measures that pass both houses must be signed into law by Democratic Gov. Tony Evers, who has made improving water quality a priority.

Under Evers, the state Department of Natural Resources has started studying water quality in southwestern Wisconsin, educating residents about the dangers of lead poisoning, creating restrictions on manure and fertilizer in areas prone to groundwater pollution and is developing standards for pollutants found in industrial products known as PFAS.

They are also known as forever chemicals because they dont break down naturally and can accumulate in the body. Studies have shown the chemicals can increase the risk of cancer, weaken the immune system and affect cholesterol levels, childhood behavior and the ability to get pregnant.

One bill up for passage creates a state-run program to more quickly collect and dispose of firefighting foam, one of the sources of PFAS.

Excerpt from:
Wisconsin Assembly to vote on bills fighting water pollution - WSAW

Read More...

Vaccine hesitancy in Turkey: An increasing threat to herd immunity – Daily Sabah

February 18th, 2020 5:52 pm

Despite public mistrust, most scientists claim that people's refusal to be vaccinated or have their children vaccinated poses an increasing threat to the population's resistance to disease.

Speaking on anti-vaccination tendencies, Infectious Diseases Association Chairman Mehmet Ceyhan told Anadolu Agency (AA) that "vaccine hesitancy" reluctance or refusal to use vaccinations is on the increase around the world and in Turkey.

Vaccine hesitant individuals hold varying degrees of indecision about specific vaccines or vaccinations in general.

Vaccine hesitancy is influenced by several factors, mainly from social pressure from society, which includes the spread of misinformation on social media, influential leaders' discourses on vaccine doubt and competence of health professionals and services, social groups and others, Ceyhan said. Anti-vaccination is one of the many factors causing vaccine hesitancy, he said, adding that vaccine rejection is among the consequences of vaccine hesitancy.

Vaccine hesitancy in Turkey

Commenting on increasing vaccine hesitancy in Turkey, Ceyhan said some people claim the substances in vaccines can lead to autism and infertility or cause permanent damage to the body.

Vaccines are much more reliable than medications, he said, noting that vaccines do not cause autism, nor have an impact on children's ability to walk.

The doctor underlined that vaccines cause "no serious" side effects.

Touching on substances like aluminum or mercury in vaccines, he said: "A sum of mercury compounds used to be added to the vaccines to ensure that vaccines were free from bacterial contamination when vaccines were produced in multi-dose bottles."

"But, nowadays, no vaccine contains mercury. Since all vaccines are now in single-dose packages, it is no longer necessary to add a mercury compound," he stressed.

On the other hand, speaking on the allegation that flu vaccines contain aluminum, which causes Alzheimer's, he said: "Aluminum in the vaccine is thousands of times less than the risk level."

He said aluminum in vaccines is low and not hazardous, adding that the total amount of aluminum in all the vaccinations is 5 milligrams.

"However, with drinking water, people consume hundreds of times more aluminum than that," he said. Although vaccination is not compulsory in Turkey, the need for it is strong he added.

Herd immunity

To maintain herd protection against disease within a population, 95% of people must be vaccinated. Turkey's rate of vaccination in 2018 was 96%, while it rose to 98% in 2019, according to Turkey's health ministry.

"No vaccine alone provides a person with full protection from the disease. However, if the majority of society is vaccinated, the vaccine prevents the spreading of diseases," the doctor said.

In this case, he said, the risk of transmission of the disease to the 1-3% of unvaccinated people will be eliminated.

Ceyhan went on to say that once herd immunity is achieved, infection risk is greatly reduced.

"However, if more than 5% of children are not vaccinated, the proportion of unprotected people reaches 6-8%, together with 1-3% of unvaccinated people. In this case, unvaccinated children would be at risk for vaccine-preventable diseases."

For this reason, many countries had to enact laws on vaccination to prevent measles outbreaks, he underlined.

Vaccine rejection threatens public health

The vaccination resistance poses an "increasing threat" in terms of public health, and families should be informed and conscious about this issue, Emine elik, a pediatrician at a training and research hospital in Ankara, told Anadolu Agency (AA).

"Unfortunately, some families do not want to get vaccinated due to hearsay information and thoughts that do not have a scientific basis," she said.

elik feels sorry that some of her colleagues "misled society" with uncertain information.

"Because, if families realize the importance of vaccination for their children, this negative situation will disappear by itself," she underlined.

The pediatrician stressed that vaccination resistance has become a "serious problem" not only in Turkey but all over the globe, noting that an increase in measles cases in the U.S., European countries and Turkey last year was a result of avoiding vaccination.

"Although adverse outcomes that may occur as a result of vaccination are very rare, they are at a level that should be ignored besides the benefits of vaccination," she warned.

Importance of child vaccination

In the past, when people were not vaccinated, there were mass child deaths, and society struggled with outbreaks, the doctor said.

elik highlighted that common childhood diseases in unvaccinated societies have mostly resulted in deaths or severe sequelae and disabilities.

She underlined that the frequency of many diseases can be reduced by vaccinating children.

With vaccinations, she said, it can be ensured that permanent or temporary additional disease complications would occur less frequently.

elik said even if vaccinated children get a disease, the vaccination helps to overcome illness in a more "smooth" way.

Noting that vaccinations do not contain substances harmful to children's health, elik said: "On the contrary, vaccines are made to strengthen the immune system and to increase the body's resistance to common and serious diseases."

The doctor urged that the vaccinated child develops immunity during a certain period and after encountering the disease factor, "gives a quick and strong response" and gets rid of being sick or suffering from the disease.

"We also question (parents) whether the child's vaccinations are complete while prescribing some treatments, and unfortunately, we have to apply heavier treatments to unvaccinated children while we can treat the vaccinated children more moderately."

Additionally, stressing the necessity and importance of following the immunization or vaccination schedule, elik said the schedules are being prepared specifically for each community in line with statistical data and by considering diseases that are common in that community.

She noted that the schedule is subject to changes in line with the needs and scientific data of the society over time.

Modern medicine's greatest success stories

The World Health Organization (WHO) refers to immunization as "one of modern medicine's greatest success stories" and a process whereby a person is made "immune or resistant" to an infectious disease, typically by the use of a vaccine.

The U.N. agency estimated around 19.4 million children globally under the age of 1 did not receive basic vaccines as of December.

"Vaccines stimulate the body's immune system to protect the person against subsequent infection or disease," it says.

The WHO said immunization is a "proven tool" for controlling and eliminating life-threatening infectious diseases, while the organization estimates immunization is estimated to avert between 2 million and 3 million deaths each year, adding that vaccines have prevented at least 10 million deaths between 2010 and 2015.

"It is one of the most cost-effective health investments, with proven strategies that make it accessible to even the most hard-to-reach and vulnerable populations," it said.

Besides preventing sickness and death associated with infectious diseases such as diarrhea, measles, pneumonia, polio and whooping cough, vaccinations hold up broader gains in education and economic development, according to the WHO.

"An additional 1.5 million deaths could be avoided, however, if global vaccination coverage improves," it said.

See the original post:
Vaccine hesitancy in Turkey: An increasing threat to herd immunity - Daily Sabah

Read More...

Coronavirus Men more likely to catch deadly bug thanks to weaker immune systems, experts fear – The Sun

February 18th, 2020 5:52 pm

MEN are more likely to catch coronavirus because they may have a weaker immune response, experts fear.

Scientists found men made up 68 per cent of patients with the deadly illness at Wuhan University hospital last month.

4

4

The figures from a Lancet paper are based on the details of the 99 coronavirus patients admitted to the hospital in January.

They also revealed that the average age of patients was 55.5 years, including 67 men and 32 women.

Science writer Anjana Ahuja, in her column for the Financial Times, said: It is an eye-catching discrepancy.

A picture is emerging of 2019-nCoV [now COVID-19] as a novel pathogen that disproportionately affects older men, particularly those with existing illnesses such as heart disease and diabetes.

She said possible reasons for the differences between men and women could be smoking, a variation of hospital treatment and hormonal differences which could impact males immune system response.

Women are prone to autoimmune diseases, which causes parts of their immune system to become stronger to compensate, resulting in a possible stronger response to the coronavirus.

Also, females routinely outlive men by six to eight years and are more likely to reach their first birthday, according to the World Health Organization.

Stanley Perlman, an immunologist at the University of Iowa and his colleagues suggested that hormones, including Oestrogen, could be a possible defence against the virus.

Prof Perlman studied how SARS a sister disease of the new coronavirus called Covid-19 impacts male and female mice.

4

What to do if you're worried you've got coronavirus

BRITISH health chiefs have raised the coronavirus risk to the public from low to moderate.

Health professionals are working to contact anyone who has been in close contact with people who have coronavirus.

The majority of those who have been infected with the virus so far have either visited China or been in close contact with someone who has.

But if you are concerned known the signs is one of the best ways to protect yourself from 2019-nCoV.

Symptoms usually include:

In most cases, you won't know whether you have a coronavirus or a different cold-causing virus.

But if a coronavirus infection spreads to the lower respiratory tract, it can cause pneumonia, especially in older people, people with heart disease or people with weakened immune systems.

It is incredibly contagious and is spread through contact with anything the virus is on as well as infected breath, coughs or sneezes.

The best way to prevent catching any form of coronavirus is to practice good hygiene.

If you have cold-like symptoms, you can help protect others by staying home when you are sick and avoiding contact with others.

You should also cover your mouth and nose with a tissue when you cough and sneeze then throw it away and wash your hands.

Cleaning and disinfecting objects and surfaces which you may have touched is also important.

If you have returned from Wuhan in the last 14 days:

If you are in Northern Ireland, call your GP.

Please follow this advice even if you do not have symptoms of the virus.

Meanwhile, leading symptom-checking provider to the NHS Doctorlink has been updated to help identify patients' risk of having coronavirus.

Source: NHS

He concluded that male mice were affected in greater number, while adding that his study was consistent across coronaviruses as well.

Two studies on SARS and MERS patients found that males had a higher death rate for both diseases.

One study showed that out of 1,800 SARS patients men had a nine per cent higher date rate.

Some scientists are now convinced that these sex differences in clinical data reflect a genuine male vulnerability to coronavirus

A 2019 study of 229 Mers patients showed found that males had a six per cent higher death rate over females.

Anjana said:Some scientists are now convinced that these sex differences in clinical data reflect a genuine male vulnerability to coronavirus, rather than a bias in exposure.

The observations add to growing evidence that immunologically speaking, men are the weaker sex.

Thekiller bughas now claimed at least 1,367 lives and infected more than 60,000 people worldwide since the outbreak began two months ago.

Nine people have been confirmed as having the bug in the UK, while 14 people have tested positive in the US.

It comes as a new diagnostic method has led the Chinese province at the epicentre of a coronavirus outbreak to report a record rise in deaths and thousands more cases today.

The central province of Hubei had previously only allowed infections to be confirmed by RNA tests, which can take days to process.

4

BALD TRUTHTearful nurses 'forced' to shave their heads before going to virus epicentre

Live Blog

KILLER VIRUSHotel near London's Heathrow CLOSED and designated as quarantine centre

DARTH VIRUSCoronavirus cleaner in 'Star Wars stormtrooper' mask disinfects GP surgery

VIRUS HATE5 racist attacks linked to coronavirus as student told 'go back to your country'

seasickBrits trapped on cruise test positive for coronavirus & husband can't stop vomiting

PLAGUE-BUSTER TANKRemote-controlled mini-tank used to disinfect areas hit by coronavirus

VIRUS FEARSLuxury mall loved by Chinese tourists is deserted after coronavirus outbreak

APPLE CRUMBLESApple hit by coronavirus as disease sparks iPhone shortages and low revenues

PLAGUE PROVINCEChina puts 58m in lockdown indefinitely as towns and villages 'sealed shut'

FACE UNLOCKSurgical masks that look like your face target coronavirus-fearing phone owners

RNA, or ribonucleic acid, carries genetic information that enables identification of organisms such as viruses.

But it has begun using quicker computerised tomography (CT) scans, which reveal lung infections, to confirm virus cases, health officials said.

Meanwhile, top officials in Hubei province - where the outbreak began in the capital city of Wuhan - were replaced.

Former Shanghai mayor Ying Yong is to replace Jiang Chaoliang as party chief in central Hubei, while two other senior officials have been removed.

Continued here:
Coronavirus Men more likely to catch deadly bug thanks to weaker immune systems, experts fear - The Sun

Read More...

Page 698«..1020..697698699700..710720..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick